WO2023090372A1 - プロモーター活性化配列、そのプロモーター活性化配列を含む発現ベクター、及びその発現ベクターを含む哺乳動物細胞 - Google Patents
プロモーター活性化配列、そのプロモーター活性化配列を含む発現ベクター、及びその発現ベクターを含む哺乳動物細胞 Download PDFInfo
- Publication number
- WO2023090372A1 WO2023090372A1 PCT/JP2022/042594 JP2022042594W WO2023090372A1 WO 2023090372 A1 WO2023090372 A1 WO 2023090372A1 JP 2022042594 W JP2022042594 W JP 2022042594W WO 2023090372 A1 WO2023090372 A1 WO 2023090372A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- cells
- promoter
- human
- sequence
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 88
- 210000004962 mammalian cell Anatomy 0.000 title claims abstract description 29
- 230000003213 activating effect Effects 0.000 title abstract description 20
- 108020004414 DNA Proteins 0.000 claims abstract description 85
- 239000013598 vector Substances 0.000 claims description 267
- 210000004027 cell Anatomy 0.000 claims description 209
- 108090000623 proteins and genes Proteins 0.000 claims description 144
- 230000014509 gene expression Effects 0.000 claims description 73
- 241000282414 Homo sapiens Species 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 44
- 210000000688 human artificial chromosome Anatomy 0.000 claims description 35
- 238000011144 upstream manufacturing Methods 0.000 claims description 31
- 230000004913 activation Effects 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 210000001988 somatic stem cell Anatomy 0.000 claims description 10
- 210000000723 mammalian artificial chromosome Anatomy 0.000 claims description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 9
- 210000004102 animal cell Anatomy 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 3
- 101000958041 Homo sapiens Musculin Proteins 0.000 claims description 2
- 102000046949 human MSC Human genes 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 abstract description 31
- 125000003729 nucleotide group Chemical group 0.000 abstract description 31
- 241000124008 Mammalia Species 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 66
- 239000012634 fragment Substances 0.000 description 50
- 238000000034 method Methods 0.000 description 47
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 36
- 239000002609 medium Substances 0.000 description 32
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 101150109071 UBC gene Proteins 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 108010054624 red fluorescent protein Proteins 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 210000004507 artificial chromosome Anatomy 0.000 description 17
- 210000000349 chromosome Anatomy 0.000 description 15
- 238000010276 construction Methods 0.000 description 13
- 210000003917 human chromosome Anatomy 0.000 description 13
- 101100315768 Homo sapiens UBC gene Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229930193140 Neomycin Natural products 0.000 description 11
- 108091006047 fluorescent proteins Proteins 0.000 description 11
- 102000034287 fluorescent proteins Human genes 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 229960004927 neomycin Drugs 0.000 description 11
- 230000006698 induction Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108010091086 Recombinases Proteins 0.000 description 9
- 102000018120 Recombinases Human genes 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 8
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 8
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009126 molecular therapy Methods 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 210000002230 centromere Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 4
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 101150086694 SLC22A3 gene Proteins 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000012212 insulator Substances 0.000 description 4
- 101150111214 lin-28 gene Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102100037935 Polyubiquitin-C Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101150048584 TRM3 gene Proteins 0.000 description 3
- 108010056354 Ubiquitin C Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 238000003163 cell fusion method Methods 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101150108980 DHX37 gene Proteins 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101000864678 Homo sapiens Probable ATP-dependent RNA helicase DHX37 Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100030093 Probable ATP-dependent RNA helicase DHX37 Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- -1 locus Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 101150087840 UL11 gene Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045429 human PGK1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Definitions
- the present invention relates to a nucleotide sequence capable of activating a promoter, an expression vector containing the promoter activation sequence, and a mammalian cell containing the expression vector. Furthermore, the present invention relates to efficient methods for producing proteins intended for expression using said mammalian cells.
- the target gene is stably and highly expressed.
- promoter sequences of housekeeping genes which are commonly expressed in many tissues and cells at a certain level and participate in maintaining cell functions, are used as promoters for expressing target genes. It is however, there are cases where sufficient expression of the target gene cannot be obtained even when the promoter sequence of the housekeeping gene is used. Therefore, it is desired to identify a nucleotide sequence (hereinafter referred to as a promoter activation sequence) that has the function of activating a promoter and enables stable high expression of a target gene introduced into mammalian cells.
- a promoter activation sequence a nucleotide sequence
- the human ubiquitin C (hereinafter abbreviated as UbC) gene is one of the housekeeping genes, and the UbC gene is widely expressed in somatic cells including fibroblasts.
- the promoter sequence of the UbC gene is known to exist in a region of about 1.3 kb on the 5'-end side from the UbC gene initiation codon, and is widely used for the purpose of expressing target genes in animal cells.
- Non-Patent Document 1 and Patent Document 1 disclose a DNA fragment of about 15 kb located upstream of the human UbC gene promoter. Furthermore, these documents indicate that the addition of this approximately 15 kb DNA fragment during vector construction enhances the activity of the UbC gene promoter.
- Non-Patent Document 1 and Patent Document 1 are as long as about 15 kb, they are often accompanied by technical difficulties when performing genetic manipulations, and there is a problem that the scope of their use is limited. .
- this approximately 15-kb DNA fragment is derived from the genome upstream of the UbC gene, it was thought to have no effect on commonly used promoters other than the UbC gene.
- Non-Patent Document 2 discloses that a 1.5 kbp sequence (A2UCOE) with anti-silencing activity was identified. Furthermore, Non-Patent Document 2 discloses that A2UCOE and fragments thereof exhibited anti-silencing effects on the activity of the splenic focal-forming virus (SFFV) promoter.
- A2UCOE 1.5 kbp sequence
- SFFV splenic focal-forming virus
- Non-Patent Document 3 and Patent Document 2 disclose that SURF-UCOE, an approximately 1-kb anti-silencing sequence derived from the human SURF1-SURF2 gene region, was identified. Furthermore, Non-Patent Document 3 and Patent Document 2 disclose that SURF-UCOE and its partial sequences showed anti-silencing against the activity of EF1 ⁇ , PGK, CMV, and RSV promoters.
- Non-Patent Document 2 Non-Patent Document 3, and Patent Document 2 are related to suppression of silencing in promoters linked to UCOE within human gene regions.
- UCOE contains an endogenous promoter sequence, protein-encoding exons and introns, when a target gene is expressed under the control of a given promoter, transcription from the endogenous promoter contained in UCOE and , there is concern that the presence of exons/introns may have unintended consequences.
- Non-Patent Document 4 discloses that D424, a 3.3-kb microsatellite sequence present in the telomeric region of human chromosome 4, and its partial sequence suppress silencing of human EF1 ⁇ promoter activity.
- the above D424 and its partial sequence contain the open reading frame (ORF) of the DUX gene. Therefore, when a gene is expressed by adding D424 and its partial sequence, there is a concern that the protein encoded by the ORF will also be expressed.
- the object of the present invention is to provide a new means that enables stable high expression of the target gene. More specifically, it is to obtain a promoter activating sequence that is an upstream genomic sequence of the human UbC gene promoter and has a smaller size than the promoter activating sequences of Patent Document 1 and Non-Patent Document 1.
- the present inventors found that a DNA fragment containing the nucleotide sequence shown in SEQ ID NO: 1 activates the promoter. Furthermore, an expression vector containing the promoter activating sequence, promoter and target gene was constructed and constructed into mammalian cells into which the expression vector was introduced. The present inventors have also found that silencing is suppressed in the mammalian cells and that the target gene can be stably expressed at a high level, thus completing the present invention.
- the present invention has the following features (1) to (17).
- a promoter activation sequence comprising 850 or more base sequences in the base sequence shown in SEQ ID NO: 1 or a base sequence having 85% or more sequence identity with it.
- An expression vector comprising the promoter activation sequence of (1), a promoter, and a DNA of interest.
- the expression vector according to (3), wherein the constitutive expression promoter is selected from the group consisting of EF1 ⁇ promoter, PGK promoter, and UBC promoter.
- the cells according to (10), wherein the human pluripotent stem cells are human iPS cells or human ES cells, and the human somatic stem cells are human MSC cells.
- the mammalian cell according to any one of (8) to (13) is cultured in a medium for animal cell culture, and the protein encoded by the DNA of interest is collected from the culture obtained by the culture.
- a method for producing a protein encoded by said DNA of interest comprising: (16) A method of suppressing silencing of the DNA of interest in a cell by introducing the expression vector according to any one of (2) to (7) into the cell. (17) A method of enhancing expression of the DNA of interest in a cell by introducing the expression vector according to any one of (2) to (7) into the cell.
- This specification includes the disclosure of Japanese Patent Application No. 2021-186122, which is the basis of priority of this application.
- a promoter activation sequence includes a nucleotide sequence consisting of 850 or more nucleotides in the nucleotide sequence shown in SEQ ID NO:1. Furthermore, the present invention provides an expression vector comprising the promoter activation sequence, promoter and target gene.
- the target gene can be stably and efficiently expressed in mammalian cells into which the expression vector has been introduced.
- FIG. 1 is a genetic map around the sequence of the present application (SEQ ID NO: 1: about 2.5 kb). This genetic map shows the region from 124,910,000 to 124,955,000 of human chromosome 12 obtained from the USCC genome browser.
- the bar line shown in the description "sequence of the present application (approximately 2.5 bp)" indicates the region corresponding to the base sequence shown in SEQ ID NO: 1 (2549 bp).
- the bar indicated by the description "about 0.8 bp)” is the region corresponding to the nucleotide sequence indicated by about 0.8 bp in SEQ ID NO: 1 (2549 bp) used in the examples below.
- FIG. 2 shows a scheme for producing HAT-resistant clones in which one copy of the expression unit is inserted into 21HAC2.
- FIG. 3 is a diagram showing a scheme for constructing X3.1-UbCP-mCherry-SV40pA (pUms vector), which is a red fluorescent protein (mCherry) expression vector for human artificial chromosome (HAC) introduction.
- pUms vector a red fluorescent protein (mCherry) expression vector for human artificial chromosome (HAC) introduction.
- FIG. 4 is a diagram showing a scheme for constructing pUL0.8ms vector and pUL2.5ms vector by adding UbC gene upstream genome to pUms vector.
- Figure 5 shows a scheme for constructing the pSUL4ms vector.
- Figure 6 shows a scheme for constructing the pSUL15ms vector.
- FIG. 7 shows that CHO cells (HAT-resistant clones) introduced with 21HAC vector into which pUms vector or pUL2.5ms vector was inserted were cultured for 7 weeks after gene introduction, and FACS analysis was performed using the expression of red fluorescent protein as an index. It is the figure which compared the result. A thick box indicates the positive fraction.
- FIG. 8 is a set of photographs showing the results of observing the expression of red fluorescent protein in MSC cells transfected with pUms vector, pUL0.8ms vector, or pUL2.5ms vector two weeks after transfection.
- the upper part of FIG. 8 is a bright field image, and the lower part is a red fluorescence image.
- the left side of FIG. 8 is a bright field image, and the lower part is a red fluorescence image.
- FIG. 8 is a photograph of pUms vector-introduced cells, the center is a photograph of MSC cells into which pUL0.8ms vector was introduced, and the right side is a photograph of pUL2.5ms vector-introduced cells.
- Figure 9 shows a pUbC-hKO + MCS vector (pUL vector), which is an orange expression vector for introducing human artificial chromosomes, and a pUL2.5 vector with the addition of about 2.5 kb of the human UbC gene 5' upstream genomic sequence to the pUL vector. It is a figure which shows the scheme to construct.
- FIG. 10 is a diagram showing a scheme for constructing a pSUL15 vector in which about 15 kb of genomic sequence upstream of the UbC gene 5' is added to the pSUkb vector, which is an orange expression vector for introducing a human artificial chromosome.
- FIG. 11-1 shows CHO cells (HAT-resistant clones: 6 clones each) introduced with a Basal-HAC vector into which a pUL vector, a pUL2.5 vector or a pSUL15 vector is inserted, using the expression of an orange fluorescent protein as an index. , and compare the results of FACS analysis. A thick box indicates the positive fraction.
- Top panel is FACS analysis data for CHO cells with pUL vector, median positive peak is 1300.
- the middle panel shows data from FACS analysis for CHO cells with the pUL2.5 vector, with a median positive peak of 14,400.
- the bottom figure is data from FACS analysis for CHO cells with the pSUL15 vector, with a median positive peak of 14,000.
- FIG. 11-2 shows CHO cells (HAT-resistant clones: 6 clones each) introduced with Basal-HAC vector into which pUL vector, pUL2.5 vector or pSUL15 vector is inserted, using the expression of orange fluorescent protein as an index. , and compare the results of FACS analysis. A thick box indicates the positive fraction.
- Top panel is FACS analysis data for CHO cells with pUL vector, median positive peak is 1300.
- the middle panel shows data from FACS analysis for CHO cells with the pUL2.5 vector, with a median positive peak of 14,400.
- the bottom figure is data from FACS analysis for CHO cells with the pSUL15 vector, with a median positive peak of 14,000.
- Figure 12 shows a pEFms vector, which is an mCherry expression vector using the EF1 ⁇ gene promoter, a pEF2.5ms vector obtained by adding 2.5 kb of the UbC gene upstream genomic sequence to the pEFms vector, and a pPGKms vector, which is an mCherry expression vector using the PGK gene promoter.
- FIG. 3 shows the structure of the pPGK2.5ms vector obtained by adding 2.5 kb of the UbC gene upstream genomic sequence to the pPGKms vector.
- FIG. 13 shows CHO cells (HAT-resistant cell population) introduced with a HAC vector into which a pEFms vector or a pEF2.5ms vector was inserted, after culturing for 4 weeks and 7 weeks after introduction, using the expression of red fluorescent protein as an index. It is the figure which compared the result of having performed FACS analysis. A thick box indicates the positive fraction. Left panel shows data for CHO cells with pEFms vector and right panel shows data for CHO cells with pEF2.5ms vector.
- FIG. 14 shows the CHO cells (HAT-resistant cell population) into which the HAC vector into which the pPGKms vector or the pPGK2.5ms vector was inserted were cultured for 4 weeks and 7 weeks after the introduction, using the expression of red fluorescent protein as an index. It is the figure which compared the result of having performed FACS analysis. A thick box indicates the positive fraction. Left panel is data for CHO cells with pPGKms vector and right panel is for CHO cells with pPGK2.5ms vector. The upper figure shows data after 4 weeks of culture after gene introduction, and the lower figure shows data after 7 weeks of culture after gene introduction.
- FIG. 14 shows the CHO cells (HAT-resistant cell population) into which the HAC vector into which the pPGKms vector or the pPGK2.5ms vector was inserted were cultured for 4 weeks and 7 weeks after the introduction, using the expression of red fluorescent protein as an index. It is the figure which compared the result of having performed FACS analysis. A thick box indicates the positive fraction. Left panel is
- FIG. 15 shows that human mesenchymal stem cells (HAT-resistant cell population) introduced with a HAC vector into which a pPGKms vector or a pPGK2.5ms vector was inserted were cultured for 4 weeks after introduction by electric pulse, followed by FACS analysis.
- FIG. 2 is a diagram comparing the results of FACS analysis using the expression of .
- the upper panel shows data for human mesenchymal stem cells with the pPGKms vector
- the lower panel shows data for human mesenchymal stem cells with the pPGK2.5ms vector.
- FIG. 16 is a diagram showing the structure of pUL2.5mNs vector, in which the mCherry-NeoR amplified fragment digested with SpeI and FseI was inserted into the pUL2.5ms vector digested with SpeI and FseI.
- FIG. 17 shows the structure of the pUmNs vector obtained by deleting the 2.5 kb region from the pUL2.5mNs vector.
- FIG. 18 shows that neomycin-resistant CHO cells (G418-resistant cells) into which a pUmNs vector or a pUmL2.5ms vector-inserted HAC vector was introduced were cultured for 2 weeks after introduction by electric pulse, followed by FACS analysis, and expression of red fluorescent protein.
- the upper panel shows data for G418-resistant cells with the pUmNs vector
- the lower panel shows data for human mesenchymal stem cells with the pUL2.5mNs vector.
- the number of mCherry-positive (P7 fraction) cells was 1136 out of 20826 (5.5%) relative to the total number of cells.
- the number of mCherry-positive (P7 fraction) cells was 1481 out of 12595 (11.8%) relative to the total number of cells.
- FIG. 20-1 shows the results of FACS analysis of human iPS clones into which a Basal-HAC vector containing a pUL vector or pUL2.5 vector was introduced, using the expression of orange fluorescent protein as an index. .
- FIG. 20-1 shows data of FACS analysis of representative clones, and the part surrounded by a thick square indicates the Kusabira Orange (KO)-positive fraction.
- FIG. 20-2 shows human iPS clones (HAT-resistant clones: 12 clones each) into which a Basal-HAC vector inserted with a pUL vector or pUL2.5 vector was introduced, using the expression of orange fluorescent protein as an index, FACS It is the figure which compared the result of having analyzed.
- FIG. 20-2 shows the average fluorescence intensity of KO-introduced iPS clones. The bar on the left side of FIG.
- FIG. 20-2 shows the average fluorescence intensity of human iPS clones into which the pUL vector was introduced, and the value on the right side shows the average fluorescence intensity of the human iPS clones into which the pUL2.5 vector was inserted. *P ⁇ 0.01 indicates that there is a significant difference at the significance level of 1% as a result of the t-test.
- a population of neomycin-resistant CHO cells (G418-resistant cells) into which a pUmNs vector or a pUmL2.5ms vector-inserted HAC vector was introduced was subjected to FACS analysis 2 weeks, 4 weeks, or 7 weeks after introduction by electric pulse. , the ratio of strongly positive mCherry to the total number of cells was evaluated.
- the portion surrounded by a thick box in FIG. 21-1 indicates the mCherry-Neo positive fraction (P6).
- the horizontal axis indicates mCherry fluorescence intensity, and the vertical axis indicates Count.
- a population of neomycin-resistant CHO cells (G418-resistant cells) into which a pUmNs vector or a pUmL2.5ms vector-inserted HAC vector was introduced was subjected to FACS analysis 2 weeks, 4 weeks, or 7 weeks after introduction by electric pulse. , the ratio of strongly positive mCherry to the total number of cells was evaluated.
- Figure 21-2 shows the number of cells in the mCherry strongly positive fraction (P6 in Figure 21-1) relative to the total number of cells at 2 weeks (2 weeks), 4 weeks (4 weeks), and 7 weeks (7 weeks) after introduction.
- FIG. 23 shows the results of examining the anti-silencing effect and activity-enhancing effect of additional sequence elements for the EF1A-mCherry-NeoR expression unit in random insertion gene transfer into CHO cells.
- a neomycin-resistant CHO cell population into which a pEFmNs vector or a HAC vector into which a pEFmNsms vector was inserted was cultured for 4 weeks after introduction by electric pulse, and FACS analysis was performed using the expression of red fluorescent protein as an indicator, and the results were compared.
- the first to second figures from the top are FACS analysis data of CHO cells carrying the pEF2.5mNs vector, and the third to fifth figures from the top are FACS analysis data of CHO cells carrying the pEFmNs vector.
- the median mCherry fluorescence intensity in the total number of cells and the percentage of mCherry-positive cells are also shown.
- the promoter activating sequence of the present invention includes a sequence of 850 or more nucleotides in the nucleotide sequence shown in SEQ ID NO: 1 or a nucleotide sequence having mutations in the nucleotide sequence.
- the nucleotide sequence represented by SEQ ID NO: 1 is a sequence located upstream of the expression promoter of the UbC gene on human chromosomal DNA. More specifically, the nucleotide sequence represented by SEQ ID NO: 1 is a 2549 bp nucleotide sequence corresponding to positions 124,927,045 to 124,929,593 of human chromosome 12.
- the base sequence of human chromosome 12 is disclosed as NC_000012.12 in GenBank of the National Center for Biotechnology Information (NCBI). Table 1 shows the base sequence of SEQ ID NO:1.
- the promoter activation sequence of the present invention most preferably consists of the entire nucleotide sequence of SEQ ID NO:1, ie, the 2549 bp nucleotide sequence of SEQ ID NO:1.
- the promoter activation sequence of the present invention may also be a shorter partial sequence of SEQ ID NO:1. For example, it may consist of 1500 bp or more, 1000 bp or more, or 850 bp or more of the base sequence of SEQ ID NO:1.
- the promoter activation sequence of the present invention also includes a nucleotide sequence in which one to several nucleotides are deleted, substituted, added or inserted in the nucleotide sequence represented by SEQ ID NO:1.
- "several” means 10 or less, preferably 8 or less, more preferably 6 or less, and most preferably 4 or less.
- the promoter activation sequence of the present invention also includes a nucleotide sequence that hybridizes to the complementary strand of the nucleotide sequence shown in SEQ ID NO: 1 under stringent conditions.
- stringent conditions are, for example, the conditions described in Current Protocols in Molecular Biology, John Wiley & Sons, 6.3.1-6.3.6, 1999, for example, 6 ⁇ SSC (sodium chloride /sodium citrate)/hybridization at 45°C, followed by one or more washes in 0.2 x SSC/0.1% SDS/50-65°C.
- Hybridization conditions that give equivalent stringency can be selected as appropriate.
- Patent Document 1 and Non-Patent Document 1 disclose that an approximately 15 kb DNA sequence located upstream of the promoter of the UbC gene on human chromosomal DNA enhances gene expression.
- a genetic map of the region from 124,910,000 to 124,955,000 of human chromosome 12 obtained from the USCC genome browser is shown in FIG.
- the left-pointing arrow indicates the region where the UbC gene (left) and DHX37 gene (right) exist on chromosome 12.
- the bar line indicated by the description "this application sequence (about 2.5 bp)" is the region corresponding to the base sequence shown in SEQ ID NO: 1 (2549 bp) indicates
- the bar line on the left side of the description "15 kb region” further below shows the region corresponding to the 15 kb base sequence disclosed in Patent Document 1 and Non-Patent Document 1.
- This 15 kb base sequence corresponds to the region from 124914981 to 124929646 of human chromosome 12 (NC_000012.12 Homo sapiens chromosome 12, GRCh38.p13 Primary Assembly).
- Patent Document 1 and Non-Patent Document 1 disclose that the activity-enhancing effect decreased as the promoter activation sequence became shorter to 15 kb, 4 kb, and 1.3 kb.
- Patent Document 1 and Non-Patent Document 1 describe the production of erythropoietin from the erythropoietin gene, which is the target gene, in CHO cells into which a vector in which a 15-kb, 4-kb, or 1.3-kb promoter-activating sequence was linked to the promoter was introduced. It is disclosed that 4.5-fold, 2.5-fold, and 1.2-fold activity-enhancing effects were obtained, respectively, using the amount as an index.
- a long sequence (15 kb) has a high activity-enhancing effect, and a shorter partial sequence alone cannot achieve an activity-enhancing effect equivalent to that of a 15 kb sequence. .
- the promoter activating sequence of the present invention of about 2.5 kb sequence (SEQ ID NO: 1) of the present invention, which is the above 15 kb partial sequence, has a promoter activating effect equivalent to that of the 15 kb sequence of the prior art. was not predicted.
- nucleotide sequence (2549 bp) of SEQ ID NO: 1 of the present invention which is located about 13 kb away from the human UbC gene promoter and located near the middle of the adjacent DEAH-box helicase 37 (DHX37) gene, is about 15 kb region. It was not expected to have an equivalent activity-enhancing effect.
- the base sequence consisting of SEQ ID NO: 1 or a partial sequence thereof (that is, the promoter activation sequence of the present invention) has a function as a promoter activation sequence, and the effect is surprising. It was something.
- the expression vector of the present invention comprises 1. A promoter activating sequence, a promoter, and DNA of interest as described in .
- the DNA of interest in the present invention is a DNA for the purpose of obtaining the protein encoded by it by expression, or a DNA for achieving the desired effect of gene therapy by introducing it. It includes nucleic acids such as locus, cDNA, recombinant DNA, modified DNA.
- the target DNA includes, without limitation, for example, disease-causing genes, therapeutic genes, chromosome fragments containing these genes, genes necessary for cell differentiation, etc.
- examples include cytokines, interferons, interleukins, , chemokines (factors with cell migration activity), granulocyte colony stimulating factor, tumor necrosis factor, growth factors (e.g., platelet-derived growth factor, vascular endothelial growth factor, hepatocyte growth factor, keratinocyte growth factor, nerve growth factor, epithelial stem cell growth factors, hematopoietic stem cell growth factors, etc.), nutritional factors (e.g., neurotrophic factors, brain-derived neurotrophic factors, etc.), erythropoietin, blood coagulation proteins, platelet production promoting factors, hormones, antibodies (e.g., monoclonal antibodies, recombinant antibodies such as scFv, etc.), genes or DNA encoding proteins such as enzymes.
- cytokines e
- the DNA of interest further includes therapeutic genes or DNA associated with diseases such as muscular dystrophy, hemophilia, neurodegenerative diseases, autoimmune diseases, allergic diseases, genetic diseases, tumors, chimeric antigen receptors (CAR), T cells It can include immune system genes or DNA such as receptors (TCR), human leukocyte antigens (HLA).
- diseases such as muscular dystrophy, hemophilia, neurodegenerative diseases, autoimmune diseases, allergic diseases, genetic diseases, tumors, chimeric antigen receptors (CAR), T cells
- CAR chimeric antigen receptors
- TCR receptors
- HLA human leukocyte antigens
- protein encoded by the DNA of interest in the present invention is expressed.
- protein as used herein includes proteins, polypeptides and peptides, and may be any protein as long as it is industrially useful, preferably a human-derived protein. Examples of such proteins include any protein for use in the treatment or prevention of, or diagnosis of, the diseases mentioned above.
- the expression vector of the present invention may contain the promoter activation sequence of the present invention on the 5' side upstream or 3' side downstream of the above promoter. More preferably, the expression vector of the present invention contains the promoter activating sequence of the present invention 5' upstream of the promoter.
- any promoter can be used as the promoter contained in the vector of the present invention, as long as it can function as a promoter in mammalian cells, and is not particularly limited. Constitutive promoters are advantageous for the purposes of the present invention because they always allow a constant amount of target DNA to be expressed.
- the promoter used in the present invention is a constitutive expression promoter known in the art to activate constitutive expression of expression vectors, preferably the promoter of a housekeeping gene. .
- constitutive promoters examples include non-viral promoters such as the human polypeptide elongation factor 1 ⁇ gene promoter (EF1 ⁇ promoter), the phosphoglycerate kinase promoter (PGK promoter) and the human ubiquitin C (UBC) promoter, as well as the CMV promoter, Viral promoters such as SV40 promoter and CAG can be mentioned.
- the promoter used in the present invention is particularly preferably the EF1 ⁇ promoter, PGK promoter, or UBC promoter used in the examples below.
- the expression vector of the present invention can be constructed by inserting a DNA cassette containing the promoter activation sequence of the present invention, the promoter and the DNA of interest into the expression vector.
- the expression vector into which the promoter activating sequence, the promoter and the target DNA are introduced has a promoter at an appropriate position for expressing the target DNA inserted into the vector, and the target DNA is expressed in mammalian cells.
- DNA cassette examples include, but are not limited to, ampicillin resistance gene, HS4 (insulator sequence described below), poly A sequence, red fluorescent protein (mCherry) gene coding region sequence, UBCP Mention may be made of pUL2.5ms with the promoter sequence, the promoter activating sequence of the invention (2.5 kb) and additionally HS4 (see Figure 4 described in the Examples).
- the present invention is not limited thereto, it is preferable to use mammalian artificial chromosome vectors and plasmid vectors. However, it is not limited to this, and conventional vector systems such as viruses, YACs, BACs, PACs, cosmids, etc. can also be used in the present invention.
- mammalian artificial chromosome vectors are not particularly limited, for example, humans, monkeys, chimpanzees, primates such as gorillas, mice, rats, hamsters, rodents such as guinea pigs, cattle, sheep, Examples include ungulates such as goats, artificial chromosome vectors such as dogs and cats.
- Particularly preferred mammalian artificial chromosome vectors are Human Artificial Chromosome (HAC) vectors, Mouse Artificial Chromosome (MAC) vectors, and Rat Artificial Chromosome (RAC) vectors.
- Human artificial chromosome vector is the most suitable vector, as a specific human artificial chromosome vector, 21HAC using human chromosome 21, 14HAC using human chromosome 14, 2HAC using human chromosome 2, etc. can be mentioned.
- the "artificial chromosome vector” herein refers to the centromere of the mammal-derived chromosome, the long arm, and, if any, a fragment near the centromere of the short arm (genes are removed as much as possible.), and artificially engineered chromosomal vectors containing natural or artificial telomeres.
- Mouse artificial chromosome vectors are described, for example, in Japanese Patent No. 5557217 and Japanese Patent No. 4997544, and human artificial chromosome vectors are described, for example, in Japanese Patent No. 4895100.
- Human chromosomes for use in the production of human artificial chromosome vectors may be any of human chromosomes 1 to 22, X and Y, but preferably any of chromosomes 1 to 22.
- human iPS cell-derived chromosomes can be used as human chromosome vectors.
- Production of human artificial chromosomes for example, JP 2010-004887, methods described in WO2008 / 013067, etc., can refer to the method described in the above literature on the production of mouse artificial chromosome vector.
- Mouse chromosomes for use in the production of mouse artificial chromosome vectors may be any of mouse chromosomes 1 to 19, X and Y, but preferably any of chromosomes 1 to 19.
- the long arm fragment is, without limitation, for example, AL671968 of the long arm of chromosome 11, or BX572640 (located on the centromere side from AL671968.) , CR954170 (located on the centromere side of AL671968 and BX572640) or AL713875 (located on the centromere side of AL671968).
- the long arm fragment in the case of a mouse artificial chromosome vector derived from a mouse chromosome 15 fragment, the long arm fragment consists of a long arm fragment in which regions distal to positions such as AC121307 and AC161799 are deleted, for example.
- the long arm fragment in the case of a mouse artificial chromosome vector derived from a mouse chromosome 16 fragment, the long arm fragment consists of a long arm fragment in which regions distal to positions such as AC127687 and AC140982 are deleted, for example.
- the above artificial chromosome vector further includes loxP (Cre recombinase recognition site), FRT (Flp recombinase recognition site), ⁇ C31attB and ⁇ C31attP ( ⁇ C31 recombinase recognition site), R4attB and R4attP (R4 recombinase recognition site), TP901-1attB and TP901-1attP (TP901-1 recombinase recognition site), or Bxb1attB and Bxb1attP (Bxb1 recombinase recognition site).
- loxP Cross recombinase recognition site
- FRT Frp recombinase recognition site
- ⁇ C31attB and ⁇ C31attP ⁇ C31 recombinase recognition site
- R4attB and R4attP R4 recombinase recognition site
- the artificial chromosome vector can contain a site for inserting a desired nucleic acid sequence
- the artificial chromosome vector is introduced into any cell by incorporating the desired nucleic acid into this site Sometimes it is possible to express the desired nucleic acid.
- the object of the present invention can be achieved.
- Examples 13 and 14 are examples of not using a site-specific recombination enzyme / enzyme recognition site when inserting a DNA cassette into an artificial chromosome vector, in which case the centromere and A DNA cassette is randomly inserted into any site other than the telomere or into the genome of the cell.
- a vector such as a plasmid vector or a viral vector into which the DNA cassette is inserted
- the DNA cassette specifically or randomly into the genome of the cell.
- a technique for inserting a DNA cassette into a genome it is also possible to insert a DNA cassette at a desired target site or randomly using, for example, a gene targeting method or a genome editing technique.
- Genome editing is a technology that edits and modifies genomic DNA using artificial cutting enzymes such as TALEN (Transcription Activator-Like Effector nuclease), ZFN (Zinc Finger nuclease), CRISPR-Cas system, etc.
- TALEN Transcription Activator-Like Effector nuclease
- ZFN Zinc Finger nuclease
- CRISPR-Cas system etc.
- the CRISPR / Cas9 system was discovered from the adaptive immune mechanism against viruses and plasmids of bacteria and archaea, but the construction of the vector is relatively simple, and multiple genes can be modified at the same time.
- This system consists of a Cas9 nuclease that cleaves double-stranded DNA on the genome and a guide RNA (sgRNA or crRNA (CRISPR RNA) + tracrRNA (trans-activating CRISPR RNA)).
- DSB double-strand break
- a reporter gene may preferably be inserted into the mammalian artificial chromosome vector, in addition to the sequence of the above gene or locus of interest.
- reporter genes include, but are not limited to, fluorescent protein (e.g., green fluorescent protein (GFP or EGFP), yellow fluorescent protein (YFP), etc.) gene, tag protein-encoding DNA, ⁇ -galactosidase gene, luciferase gene and the like.
- the mammalian artificial chromosome vector may further contain a selectable marker gene.
- Selectable markers are useful in selecting cells transformed with the vector.
- selectable marker genes include positive selectable marker genes and negative selectable marker genes, or both.
- Positive selectable marker genes include drug resistance genes such as neomycin resistance gene, ampicillin resistance gene, blasticidin S (BS) resistance gene, puromycin resistance gene, geneticin (G418) resistance gene, hygromycin resistance gene, etc.
- Negative selectable marker genes include, for example, herpes simplex thymidine kinase (HSV-TK) gene, diphtheria toxin A fragment (DT-A) gene and the like. HSV-TK is commonly used in combination with ganciclovir or acyclovir.
- the artificial chromosome vector which is the expression vector in the present invention, also contains a nucleic acid insertion site into which a nucleic acid containing the promoter activation sequence, promoter, and target DNA of the present invention can be inserted, and the nucleic acid is inserted into this site. be done.
- At least one insulator sequence can be present near the nucleic acid insertion site or on both sides of the insertion site in the artificial chromosome of the present invention.
- Insulator sequences have an enhancer-blocking effect (ie, adjacent genes are not affected by each other) or a chromosomal boundary effect (separate regions that ensure gene expression from those that are repressed).
- Such sequences may include, for example, human beta globin HS1-HS5, chicken beta globin HS4, and the like.
- the promoter activation sequence of the present invention a promoter , and a nucleic acid containing the DNA of interest can be introduced. After introduction of the nucleic acid, donor cells containing the DNA of interest can be detected and recovered, for example, by HAT selection methods.
- Mammalian cells of the present invention Mammalian cells containing the expression vector of the present invention (hereinafter simply referred to as mammalian cells of the present invention) by introducing the foreign gene expression vector into mammalian cells that are host cells ) can be made.
- Mammalian cells used as host cells in the present invention are not particularly limited as long as they can cause nucleic acid amplification of the target DNA.
- cells rodent cells (hamster cells, mouse cells, rat cells, etc.).
- rodent cells hamster cells, mouse cells, rat cells, etc.
- particularly human cells and hamster cells are preferably used.
- human-derived stem cells such as human pluripotent stem cells or human somatic stem cells can be used.
- human mesenchymal stem cells MSC cells
- human induced pluripotent stem cells iPS cells
- Mouse cells or rat cells can also be mouse- or rat-derived stem cells, such as mouse- or rat-derived pluripotent stem cells or somatic stem cells.
- mouse or rat somatic stem cells it is particularly preferred to use mouse or rat MSC cells.
- mouse or rat pluripotent stem cells it is particularly preferable to use mouse or rat induced pluripotent stem cells (iPS cells), and mouse or rat embryonic stem cells (ES cells) are used. is also particularly preferred.
- Rat ES cells, as well as mouse ES cells can be obtained from rat blastocyst stage embryos or 8-cell stage embryos. It is a cell line with pluripotency and self-renewal ability, which is established from the inner cell mass of the embryo.
- hamster cells it is preferable to use Chinese hamster ovary cells (CHO cells), and more specifically, for example, CHO-K1, CHO-S, DG44, etc. are particularly preferable. be.
- CHO cells Chinese hamster ovary cells
- somatic cells include, but are not limited to, hepatocytes, enterocytes, kidney cells, splenocytes, lung cells, heart cells, skeletal muscle cells, brain cells, skin cells, bone marrow cells, fibroblasts, hematopoietic stem cells, Examples include T cells, B cells, and the like.
- embryonic stem cells or "ES cells” used herein refers to pluripotent differentiation and semi-permanent proliferative ability established from the inner cell mass of the blastocyst of a fertilized egg derived from a mammal.
- stem cells MJ Evans and MH Kaufman (1981) Nature 292: 154-156; JA Thomson et al. (1999) Science 282: 1145-1147; JA Thomson et al. (1995) Proc. Natl. Acad. Sci. USA 92:7844-7848; JA Thomson et al.(1996) Biol. Marshall (1998) Curr. Top. Dev. Biol. 38:133-165).
- iPS cells are "induced pluripotent stem cells” or "iPS cells” (K. Takahashi and S. Yamanaka (2006) Cell 126 : 663-676; K. Takahashi et al. (2007) Cell 131: 861-872; J. Yu et al. (2007) Science 318: 1917-1920).
- iPS cells are produced by introducing a specific reprogramming factor (DNA or protein) into somatic cells (including somatic stem cells), culturing them in an appropriate medium, and subculturing them in about 3 to 5 weeks. Can generate colonies.
- Reprogramming factors are, for example, the combination consisting of Oct3/4, Sox2, Klf4 and c-Myc; the combination consisting of Oct3/4, Sox2 and Klf4; the combination consisting of Oct4, Sox2, Nanog and Lin28; A combination of Sox2, Klf4, c-Myc, Nanog and Lin28 is known (K. Takahashi and S. Yamanaka, Cell 126: 663-676 (2006); WO2007/069666; M.
- the mammalian artificial chromosome vector of the present invention can be transferred or introduced into any mammalian cell.
- Techniques therefor include, for example, the micronucleus cell fusion method, lipofection, calcium phosphate method, microinjection, electroporation, etc., and the preferred method is the micronucleus cell fusion method disclosed in WO2020/075823.
- the micronucleus cell fusion method is a method of transferring the vector into another cell by micronucleus fusion between a cell that contains a mammalian artificial chromosome vector and has the ability to form micronuclei with another desired cell.
- Cells having the ability to form micronuclei are treated with a polyploid-inducing agent (e.g., colcemid, colchicine, etc.) to form micronucleated multinucleated cells, and treated with cytochalasin to form micronuclei.
- a polyploid-inducing agent e.g., colcemid, colchicine, etc.
- Mammalian cells containing the expression vector of the present invention can achieve stable and high expression of the DNA to be expressed due to the presence of the promoter activation sequence of the present invention contained in the expression vector. It is demonstrated in the examples described below that such stable high expression of the target DNA is brought about by the expression-enhancing activity and/or anti-silencing activity of the target DNA.
- Protein production method of the present invention 3 . by culturing the mammalian cells described in 1. in a medium for culturing animal cells, and collecting a protein encoded by the DNA of interest (hereinafter referred to as the desired protein) from the culture obtained by the culturing, A desired protein can be produced. This is because, as described above, the presence of the promoter activation sequence of the present invention brings about stable high expression of the target DNA.
- Cultivation of the animal cells of the present invention can be carried out according to ordinary methods used for culturing mammalian cells.
- Methods for producing the protein of the present invention include a method of producing it within the host cell, a method of secreting it outside the host cell, and a method of producing it on the extracellular membrane of the host cell. By changing , an appropriate method can be selected.
- a medium suitable for the type of cells used is selected.
- Commonly used basal media include MEM medium, DMEM medium, RPMI medium, F12 medium, Macy's 5A medium, or mixed medium thereof (eg, DMEM/F12).
- the basal medium can further be supplemented with at least one component such as serum, serum replacement, antibiotics, supplements such as glutamate, pyruvate and the like.
- the pH of the medium is, for example, 7.2-7.4.
- mitomycin C-treated mouse fetal fibroblast cell lines eg, STO
- vector-introduced somatic cells eg, about 10 4 to 10 5 cells/cm 2
- the basal medium is, for example, Dulbecco's Modified Eagle Medium (DMEM), Ham's F-12 medium, mixed medium thereof, or the like
- the ES cell medium is mouse ES cell medium, primate ES cell medium (Reprocell), or the like.
- human iPS cells and human ES cells can be cultured under feeder-free conditions using StemFit AK02N medium (TAKARA) that does not contain animal-derived components.
- TAKARA StemFit AK02N medium
- Rat ES cells are obtained by, for example, culturing rat blastocysts with lysed zona pellucida on mouse embryonic fibroblast (MEFF) feeders using medium containing leukemia inhibitory factor (LIF). After 10 days, the outgrowth formed from the blastocyst is dispersed, transferred onto MEF feeders and cultured, and after about 7 days, ES cells emerge.
- LIF leukemia inhibitory factor
- Cultivation is carried out in an atmosphere of air containing about 2-10% (usually about 5%) CO 2 at a temperature of about 35-40° C. (usually about 37° C.).
- the culture method may be batch culture, flask culture, fed-batch culture, continuous culture, suspension culture, shaking culture, stirring culture, circulation culture, or the like.
- a method such as passing the culture medium during culture through a hollow fiber filter to break up aggregates.
- the culture equipment equipment used for animal cell culture can be used.
- the apparatus should be equipped with ventilation, temperature control, agitation, pH and DO control functions.
- Examples of equipment include fermenter tank culture equipment, air lift culture equipment, fluidized bed culture equipment, hollow fiber culture equipment, roller bottle culture equipment, filled tank culture equipment, bag culture equipment, etc. Can be cultured.
- reporter genes that monitor the behavior and biological functions of target proteins in mammalian cells.
- a reporter gene eg, DNA encoding a fluorescent or luminescent protein
- genetic regulatory sequences eg, promoter, enhancer, etc.
- High expression of the reporter gene can increase the detection sensitivity of the reporter assay.
- the behavior of the target DNA expressed by a certain stimulus in the cell can be observed using fluorescence or luminescence as an indicator. Since such observations can usually be performed in a laboratory, cells can be cultured using a solid medium suitable for the cell type. Observation can generally be performed using a fluorescence microscope with a camera or the like.
- JP-A-2-227075 a gene amplification system using a dihydrofolate reductase gene or the like
- the supernatant or cells after centrifugation or filtration are subjected to column chromatography such as affinity chromatography, gel filtration chromatography, ion exchange chromatography, etc. It can be subjected to graphics, filters, ultrafiltration, salting out, dialysis, combinations thereof, and the like.
- the recovery method shall not be limited to the methods described above, and generally includes any method that can be used for protein purification.
- the desired protein is a glycoprotein such as an antibody
- it can be recovered using a protein A column, protein G column, protein L column, or IgG-binding peptide column.
- the cells are recovered by centrifugation after completion of the culture, suspended in an aqueous buffer, and treated with an ultrasonicator, French press, Mantongaurin homogenizer, Dynomill, or the like. to disrupt the cells using to obtain a cell-free extract.
- the usual protein isolation and purification methods such as solvent extraction, salting out with ammonium sulfate, desalting, precipitation with an organic solvent, diethylamino Anion exchange chromatography method using resins such as ethyl (DEAE)-Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Chemical), cation exchange chromatography using resins such as S-Sepharose FF (manufactured by Pharmacia) method, hydrophobic chromatography using resins such as butyl sepharose and phenyl sepharose, gel filtration using molecular sieves, affinity chromatography, chromatofocusing, or electrophoresis such as isoelectric focusing. can be used alone or in combination to obtain purified preparations.
- solvent extraction salting out with ammonium sulfate
- desalting precipitation with an organic solvent
- diethylamino Anion exchange chromatography method using resins such as ethyl (DEAE)-S
- the cells are collected and crushed in the same manner as described above, and centrifuged to collect the insoluble form of the protein as a precipitate fraction.
- the collected insoluble form of the protein is solubilized with a protein denaturant.
- a purified preparation of the polypeptide can be obtained by the same isolation and purification method as described above.
- the protein or a derivative such as a sugar modification thereof can be recovered from the culture supernatant.
- a soluble fraction is obtained by treating the culture by a technique such as centrifugation in the same manner as described above, and a purified preparation can be obtained from the soluble fraction by using the same isolation and purification method as described above. can.
- Non-Human Animals Carrying Expression Vectors of the Present Invention The present invention further provides non-human animals carrying the expression vectors of the present invention.
- non-human animals refers to animals other than humans, including primates such as monkeys and chimpanzees, rodents such as mice, rats, hamsters and guinea pigs, cattle, pigs, sheep, goats, horses and camels. It includes, but is not limited to, mammals such as ungulates such as hoofed animals.
- Non-human animals can be produced, for example, by introducing the expression vector into ES cells or iPS cells, introducing these cells into early embryos, then transplanting them into the uterus of foster mothers, and giving birth to non-human animals. .
- a method for producing the same will be described below.
- ES cells can be established and maintained by removing the inner cell mass from the blastocyst of the fertilized egg of the target animal and using mitomycin C-treated mouse fetal fibroblasts as a feeder (MJ Evans and MH. Kaufman, Nature 292:154-156 (1981)).
- iPS cells are produced by introducing a specific reprogramming factor (DNA or protein) into somatic cells (including somatic stem cells), culturing them in an appropriate medium, and subculturing them for about 3 to 5 years. Form colonies in a week.
- Reprogramming factors are, for example, the combination consisting of Oct3/4, Sox2, Klf4 and c-Myc; the combination consisting of Oct3/4, Sox2 and Klf4; the combination consisting of Oct4, Sox2, Nanog and Lin28; A combination of Sox2, Klf4, c-Myc, Nanog and Lin28 is known (K. Takahashi and S. Yamanaka, Cell 126: 663-676 (2006); WO2007/069666; M.
- the basal medium is, for example, Dulbecco's Modified Eagle Medium (DMEM), Ham's F-12 medium, mixed medium thereof, etc.
- the ES cell medium is mouse ES cell medium, primate ES cell medium (Reprocell, Japan). ) can be used.
- ES cells and iPS cells are known to contribute to the germ line
- these cells into which the expression vector of the present invention containing the DNA of interest has been introduced are introduced into early embryonic embryos of the same species of mammals from which the cells are derived.
- a non-human animal (or transgenic non-human animal) can be produced by a procedure that involves injecting an embryo, implanting the embryo into the uterus of a foster mother, and bringing it to term.
- homozygous animals and their progeny animals can be produced by mating the resulting male and female transgenic animals.
- the non-human animal when used to produce a heterologous (e.g., human) protein encoded by the DNA of interest, the endogenous gene corresponding to the DNA of interest is deleted or completely inactivated. Animals can be used.
- Gene therapy can be performed by administering the expression vector of the present invention to mammals, particularly humans, and expressing the protein encoded by the target DNA in the body of the mammal.
- Gene and cell therapy can be performed by expressing the protein encoded by the DNA of interest in the body of an animal.
- the effect of gene cell therapy can be obtained by administering or transplanting the expression vector of the present invention containing a disease-causing gene, a therapeutic gene, etc. as a target DNA, or a cell or tissue into which the expression vector has been introduced, to a patient.
- a disease-causing gene e.g., a therapeutic gene, etc.
- a target DNA e.g., a cell or tissue into which the expression vector has been introduced
- causative genes or therapeutic genes for those diseases such as chimeric antigen receptor (CAR)
- CAR chimeric antigen receptor
- the promoter (UBCP promoter, EF1 ⁇ promoter and PGK promoter) has the promoter activation sequence of the present invention (2549 bp: SEQ ID NO: 1) on the 5' side upstream of the promoter, and 3' of the promoter.
- a HAC vector was constructed with a downstream indicator gene (gene for red fluorescent protein or orange fluorescent protein). Then, the HAC vector was introduced into CHO cells or human mesenchymal cells, and the anti-silencing effect and activity enhancement effect of the promoter activation sequence of the present invention were evaluated using the expression of the indicator protein as an index. As a result, it was demonstrated that the promoter activation sequence of the present invention actually has anti-silencing effect and activity enhancement effect.
- Example 1 Construction of red fluorescent protein (mCherry) expression vector for introduction of human artificial chromosome (HAC) CHO hprt-deficient (hprt-) cell line (21HAC2 / CHOhprt-) harboring HAC vector (21HAC2); Kazuki Y et al Gene Ther 18(4):384-93 2011) investigated the anti-silencing and activity-enhancing effects of additional sequence elements on universal promoters.
- the CAG promoter-EGFP-polyA portion of the I-EGFP-I-loxP-3'HPRT vector ( Figure 2; Kazuki Y et al. Gene Ther 18(4):384-93 2011) was combined with various other expression units.
- HS4-F2 5'-ATCCATGGATCGACTCTAGAGGGACAGCC-3' (SEQ ID NO: 3)
- HS4-R1 5'-ATAACTAGTCGACGCGGCCGCCTCACTGACTCCGTCCTGGA-3' (SEQ ID NO: 4)
- mCherry expression vector by adding UbC gene upstream genomic sequence to pUms vector About 2.5 kb region (Fig. 1) within about 15 kb of human UbC gene 5' upstream genomic sequence (hereinafter referred to as UL15) or a partial fragment thereof (0. 8 kb; FIG. 1) were added, respectively, HAC introduction vectors having an expression unit consisting of UbCP / mCherry gene / SV40 poly A sequence were prepared by the following procedure (respectively, pUL0.8ms vector, pUL2.5ms vector and called).
- Two types of human UbC gene 5' upstream genomic sequences were prepared by PCR amplification using the following primers and human chromosomal BAC clone RP11-592O2 as a template. Using the following primers and Primestar GXL premix (Takara), 98°C 10 seconds ⁇ 72°C 10 minutes, 5 cycles, 98°C 10 seconds ⁇ 70°C 10 minutes, 5 cycles, 98°C 10 seconds ⁇ 68°C 10 minutes, 30 Cycle PCR reactions were performed. The amplified fragment was further digested with SalI and KpnI and the resulting fragment was cloned into the pUms vector digested with SalI and KpnI. An outline of vector construction is shown in FIG.
- pUL0.8ms-F 5'-CATGTCGACCCAGAGACAACCACAGAACC-3' (SEQ ID NO: 5)
- pUL0.8ms-R 5'-AGTGGTACCCGCACGCAGTCCCTGCTGAA-3' (SEQ ID NO: 6)
- pUL2.5ms-F 5'-CATGTCGACACCCGGAAGGCGGAGGTTAC-3' (SEQ ID NO: 7)
- pUL2.5ms-R 5'-AGTGGTACCAGGAAGTTCAGGAAATTGGC-3' (SEQ ID NO: 8)
- pSUL15ms vector A vector for introducing HAC having an expression unit consisting of UbCP/mCherry gene/SV40 polyA sequence with UL15 added was constructed by the following procedure.
- pSTV28 vector (Takara) was digested with EcoRI and XbaI, and a DNA fragment containing AscI site and SmaI site prepared by annealing the following synthetic DNA sequences was inserted to prepare pSTV28+MCS vector (Fig. 5).
- pSTV28-MCS_1 5'-CTAGACCCGGGATTGGCGCGCCG-3' (SEQ ID NO: 9)
- pSTV28-MCS_2 5'-AATTCGGCGCGCCAATCCCCGGGT-3' (SEQ ID NO: 10)
- UbCP / mCherry gene / SV40 poly to which about 4 kb region proximal to the UBC gene coding region and about 11 kb distal to the UBC gene coding region in the human UbC gene 5' upstream genomic sequence about 15 kb (hereinafter referred to as UL15) are added 2.
- a HAC introduction vector having an expression unit consisting of the A sequence; (referred to as pUL4ms vector and pUL11ms vector, respectively).
- Two types of human UbC gene 5' upstream genomic sequences were prepared by PCR amplification using the following primers, respectively, and human chromosomal BAC clone RP11-592O2 as a template.
- pUL4ms-F 5'-ACTGGTACCATCGATTCAGCCAGGCACATTAGCTC-3' (SEQ ID NO: 11)
- pUL4ms-R 5'-GAGGTCGACCGGGAGCGGGTGGGCGGCCC-3' (SEQ ID NO: 12)
- pUL11ms-F 5'-TATGTCGACATCGATATACAGACATGAGCTAATGT-3' (SEQ ID NO: 13)
- pUL11ms-F 5'-AGTGGTACCAGGAAGTTCAGGAAATTGGC-3' (SEQ ID NO: 14)
- the DNA fragment between the AscI site and the SmaI site of the pSTV28+MCS vector was replaced with the DNA fragment between the ScaI and AscI sites containing UL4-UbCP-mCherry-SV40pA of the pUL4ms vector to generate pSTV-UL4-UbCP-mCherry-SV40pA.
- Fig. 5 hereinafter referred to as pSUL4ms vector.
- the pSUL4ms vector was digested with KpnI and ClaI, and a DNA fragment between the KpnI and ClaI sites containing the UL11 sequence of the pUL11ms vector was inserted to create pSTV-UL15-UbCP-mCherry-SV40pA (Fig. 6; hereinafter, pSUL15ms vector called).
- Example 2 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on UBCP-mcherry expression unit in CHO cells 21HAC2 vector.
- the above expression vector was added to 21HAC2/CHOhprt- cells harboring the 21HAC2 vector together with the recombinase (Cre) expression vector pBS185 (Kazuki Y et al. Gene Ther 18(4):384-93 2011) to transfer NEPA21 (Nepagene, 150V, 5. 0 msec) was used to introduce by the electric pulse method.
- Re recombinase
- the cells were seeded on one 10 cm dish and cultured in Ham's F12 medium containing 2% HAT (Sigma) and 10% FBS (Nichirei) after 48 hours to obtain HAT-resistant colonies. bottom.
- the resulting HAT-resistant cell population was subjected to FACS analysis 7 weeks after introduction to evaluate the expression of red fluorescent protein.
- the results are shown in FIG.
- the mean median positive peaks of the HAT-resistant cell population transfected with the pUL2.5ms vector (4302) were higher than the mean median positive peaks of the cell population transfected with the pUms vector (1662). That is, it was shown that the addition of the 2.5 kb fragment to UBCP brought about the effect of enhancing the promoter activity.
- Example 3 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on UBCP-mcherry expression unit in human mesenchymal stem cells pUms vector, pUL0.8ms vector, pUL2.5ms vector prepared in Example 1 was inserted into the 21HAC2 vector in the 21HAC2/human immortalized mesenchymal stem cells (Okamoto T et al. BBRC 295:354-361 2002) hprt- strain. The above expression vector was transferred together with the recombinase (Cre) expression vector pBS185 (Kazuki Y et al.
- Re recombinase
- the red fluorescence intensity in the pUL2.5ms vector-introduced cells was clearly stronger than the red fluorescence intensity in the pUms vector and pUL0.8ms vector-introduced cells. That is, it was shown that addition of about 2.5 kb fragment to UBCP brings about promoter activity enhancing effect, and addition of about 0.8 kb fragment has no such effect.
- the ⁇ C31 attB-NeoR-pUbc-KO1 vector was digested with KpnI, blunt-ended and self-ligated to prepare the ⁇ C31 attB-NeoR-pUbc-KO1(KpnI-) vector (Fig. 9).
- a DNA fragment containing a SalI site and a KpnI site (multicloning site) prepared by annealing the following sequences was inserted into the SalI site upstream of the UbC promoter to construct a pUbC-hKO+MCS vector (hereinafter referred to as pUL vector.
- pUL vector pUbC-hKO+MCS vector
- a vector was constructed in the same manner as in Example 1, in which about 2.5 kb of the genomic sequence 5' upstream of the human UbC gene was added to the UBCP of the pUL vector (Fig. 9; referred to as pUL2.5 vector).
- the DNA fragment between the PvuI site and the SacI site of the pSTV28+MCS vector prepared in Example 1 was replaced with the DNA fragment between the PvuI site and the SacI site containing UbC-KO-BGHpA of the pUL vector, resulting in pSTV-UbC-hKO- A BGHpA vector was constructed (hereinafter referred to as pSUkb vector; FIG. 10).
- the pSUkb vector was digested with SalI and KpnI, and a DNA fragment containing about 15 kb of the UbC gene 5' upstream genomic sequence between the SalI site and the KpnI site of the pSUL15ms vector was inserted to prepare the pSUL15 vector (FIG. 10).
- Example 5 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on UBCP-KO expression unit in CHO cells / into the Basal-HAC vector in CHO cells.
- the above expression vector was transferred to Basal-HAC/CHO cells together with a recombinant enzyme ( ⁇ C31 integrase) expression vector (Kazuki Y et al. Molecular Therapy: Nucleic Acids 23: 629-639 2021) and NEPA21 (Nepagene, 150 V, 5.0 msec).
- ⁇ C31 integrase recombinant enzyme
- Example 6 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on UBCP-KO expression unit in human iPS cells It was inserted into the Basal-HAC vector in iPS cells (Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021). The above expression vector was introduced into Basal-HAC/human iPS cells together with a recombinant enzyme ( ⁇ C31 integrase) expression vector (Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021) by an electric pulse method.
- ⁇ C31 integrase recombinant enzyme
- FIG. 20 shows the results of evaluating the fluorescence intensity of KO in clones into which each vector was introduced. As a result, the proportion of the KO positive population when the pUL2.5 vector was introduced was higher than when the pUL vector was introduced. , showed an increased proportion of KO-expressing cells in human iPS cells.
- Example 7 Construction of mCherry expression vector using EF1A promoter added with UbC gene upstream genomic sequence Human elongation factor 1 ⁇ 1 (EF1 ⁇ ) gene promoter (EF1AP; about 1.2 kb, Qin JY et al. PLoS One.5 (5 ): e10611 2010), the red fluorescent protein mCherry gene coding region, and the SV40polyA sequence were designed to have NotI sites at both ends, and the sequence was synthesized by Vector Builder.
- EF1 ⁇ Human elongation factor 1 ⁇ 1 gene promoter
- the EF1A-mCherry-SV40pA sequence (NotI fragment) derived from the synthetic DNA was inserted into the X3.1-MCS vector digested with NotI in the same manner as in Example 1 to prepare X3.1-EF1A-mCherry-SV40pA. (hereinafter referred to as pEFms vector; FIG. 12).
- pEFms vector a HAC introduction vector having an expression unit consisting of EF1AP/mCherry gene/SV40 poly A sequence to which about 2.5 kb of the human UbC gene 5′ upstream genome sequence was added was prepared (hereinafter referred to as pEF2 .5 ms vector; FIG. 12).
- Example 8 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on EF1AP-mcherry expression unit in CHO cells 21HAC2 vector.
- the above expression vector was transferred together with the recombinase (Cre) expression vector pBS185 (Kazuki Y et al. Gene Ther 18(4):384-93 2011) into 21HAC2/CHOhprt- cells harboring the 21HAC2 vector by NEPA21 (Nepagene, 150V, 5 .0 msec) were introduced by the electrical pulse method.
- Re recombinase
- the cells were seeded on one 10 cm dish and cultured in Ham's F12 medium containing 2% HAT (Sigma) and 10% FBS (Nichirei) after 48 hours to obtain HAT-resistant colonies. bottom.
- the obtained HAT-resistant cell population was subjected to FACS analysis 4 weeks and 7 weeks after introduction to evaluate the expression of red fluorescent protein.
- the results are shown in FIG.
- the ratio of the mcherry-negative population was higher than in the positive population, but in the pUL2.5 vector-introduced cell population, almost no negative population was observed. That is, it was shown that addition of a 2.5 kb fragment to EF1AP resulted in an anti-silencing effect.
- Example 9 Construction of mCherry expression vector using PGK promoter to which UbC gene upstream genomic sequence was added Human phosphoglycerate kinase 1 (PGK) gene promoter (PGKP; about 0.5 kb, Kita-Matsuo H et al. PLoS One. 4(4): e5046. 2009), the red fluorescent protein mCherry gene coding region, and the expression unit consisting of the SV40polyA sequence was designed so that NotI sites were arranged at both ends, and the sequence was prepared by Vector Builder. Synthesized.
- PGK Human phosphoglycerate kinase 1
- the PGKP-mCherry-SV40pA sequence (NotI fragment) derived from the synthetic DNA was inserted into the X3.1-MCS vector digested with NotI in the same manner as in Example 1 to prepare X3.1-PGKP-mCherry-SV40pA ( Hereafter referred to as the pPGKms vector; FIG. 12).
- a HAC introduction vector having an expression unit consisting of PGKP/mCherry gene/SV40 poly A sequence to which about 2.5 kb of the human UbC gene 5′ upstream genomic sequence was added was prepared (hereinafter referred to as pPGK2. Called 5 ms vector; FIG. 12).
- Example 10 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on PGKP-mcherry expression unit in CHO cells - inserted into the 21HAC2 vector in cells.
- the above expression vector was transferred together with the recombinase (Cre) expression vector pBS185 (Kazuki Y et al. Gene Ther 18(4):384-93 2011) into 21HAC2/CHOhprt- cells harboring the 21HAC2 vector by NEPA21 (Nepagene, 150V, 5 .0 msec) were introduced by the electric pulse method.
- Re recombinase
- the cells were seeded on one 10 cm dish and cultured in Ham's F12 medium containing 2% HAT (Sigma) and 10% FBS (Nichirei) after 48 hours to obtain HAT-resistant colonies. bottom.
- the obtained HAT-resistant cell population was subjected to FACS analysis 4 weeks and 7 weeks after introduction to evaluate the expression of red fluorescent protein.
- the results are shown in FIG.
- the ratio of the mcherry-negative population was higher than that of the mcherry-positive population.
- almost no negative population was observed in the cell population into which the pPGK2.5ms vector was introduced. That is, it was shown that the addition of the 2.5 kb fragment to EF1AP confers an anti-silencing effect.
- Example 11 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on PGKP-mcherry expression unit in human mesenchymal stem cells - inserted into the 21HAC2 vector in cells.
- the above expression vector was transferred together with the recombinase (Cre) expression vector pBS185 (Kazuki Y et al. Gene Ther 18(4): 384-93 2011) into 21HAC2/hiMSChprt- cells harboring the 21HAC2 vector with NEPA21 (Nepagene, 150V, 5 .0 msec) were introduced by the electrical pulse method.
- Re recombinase
- the cells were seeded on a 10 cm dish and cultured in DMEM medium containing 2% HAT (Sigma) and 10% FBS (Nichirei) after 48 hours to obtain HAT-resistant colonies.
- the resulting HAT-resistant cell population was subjected to FACS analysis 4 weeks after introduction to evaluate the expression of red fluorescent protein.
- the results are shown in FIG.
- the ratio of the mcherry-negative population was higher than that of the mcherry-positive population.
- almost no negative population was observed in the cell population into which the pPGK2.5ms vector was introduced. That is, it was shown that the addition of the 2.5 kb fragment to PGKP confers an anti-silencing effect.
- Example 12 Construction of mCherry expression vector for random insertion with addition of UbC gene upstream genomic sequence
- a random insertion vector having an expression unit consisting of a neoR (neomycin resistance) fusion gene/SV40 polyA sequence was constructed by the following procedure (referred to as pUL2.5mNs vector).
- PCR was performed using the mCherry_NeoR-CMV_Luciferase vector synthesized by Vector Builder as a template to amplify a fragment with SpeI and FseI sites added to both ends of mCherry-NeoR.
- primers and KOD One PCR Master Mix TOYOBO
- the pUL2.5mNs vector was prepared by inserting the above mCherry-NeoR amplified fragment digested with SpeI and FseI into the pUL2.5ms vector prepared in (Example 1) digested with SpeI and FseI.
- An outline of the construction of the pUL2.5mNs vector is shown in FIG.
- the pUmNs vector obtained by deleting the above-mentioned approximately 2.5 kb region from the pUL2.5mNs vector was prepared by digesting the pUL2.5mNs vector with SalI and KpnI and blunt-ending it with a Blunting Kit (TAKARA). An outline of the structure of the pUmNs vector is shown in FIG.
- Example 13 Examination of the anti-silencing effect and activity-enhancing effect of additional sequence elements on the UbCP-mCherry-NeoR expression unit in random insertion gene transfer with CHO 21HAC2/CHOhprt- cells.
- a recombinant enzyme (Cre) expression vector was not introduced at the same time. It renders neomycin (G418) resistant when the introduced vector is randomly inserted into the CHO cell genome.
- ScaI restriction enzyme
- the cells were seeded on two 10 cm dishes, and after 48 hours, cultured in Ham's F12 medium containing 800 ⁇ g/mL G418 (Wako) and 10% FBS (Nichirei) to form drug-resistant colonies. obtained. Two weeks after the introduction, FACS analysis was performed on the resulting cell population in which drug-resistant colonies were mixed, and red fluorescence intensity was compared. The results are shown in FIG. In the G418-resistant cells carrying the pUmNs vector, the number of mCherry-positive (P7 fraction) cells was 1136 out of 20826 (5.5%) relative to the total number of cells.
- 21-2 shows FACS analysis of G418-resistant cells 2 weeks, 4 weeks, or 7 weeks after introduction by electric pulse, and measuring the ratio of mCherry strongly positive fraction (P6) to the total number of cells. .
- the percentage of cells in the mCherry strongly positive fraction (P6) exhibiting a fluorescence intensity of 1000 or more was 10 in all G418-resistant cells at week 4 and week 7 harboring the pUL2.5mNs vector. % or more (average of week 4: 15.87%, average of week 7: 13.10%), whereas in G418-resistant cells with pUmNs vectors, all were 0.1% or less. there were.
- the proportion of the mcherry-positive population when the pUL2.5mNs vector was introduced was higher than when the pUmNs vector was introduced. It was shown that the proportion of mcherry-expressing cells was increased.
- Example 14 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element for UbCP-mCherry-NeoR expression unit in random insertion gene transfer in human iPS cells pUmNs vector and pUL2.5mNs prepared in Example 12
- the vector was introduced into human iPS cells (201B7: RIKEN CELL BANK No. HPS0063).
- a recombinant enzyme (Cre) expression vector is not introduced at the same time. It renders neomycin (G418) resistant when the introduced vector is randomly inserted into the CHO cell genome.
- the vector was digested with restriction enzyme ScaI, it was recovered by ethanol precipitation and introduced into 201B7 by electric pulse method using NEPA21 (Nepagene, 175 V, 2.5 msec). After induction by electric pulse, the cells were seeded on two 10-cm dishes and cultured in StemFit medium (TAKARA) containing 70 ⁇ g/mL G418 (Wako) after 48 hours to obtain drug-resistant colonies. Seven days after the introduction, one 10 cm dish was treated with methanol for 15 minutes and then stained with a CBB staining solution (0.25% CBB/10% ethanol/40% methanol) for 15 minutes. The stained 10 cm dish was photographed, and the number of colonies was counted and compared.
- TAKARA StemFit medium
- the drug-resistant colony appearance rate increased due to the anti-silencing effect and activity-enhancing effect of the 2.5-kb fragment on UBCP (Fig. 19).
- one 10 cm dish is cultured with the G418 concentration changed to 50 ⁇ g/ml from 8 days after the introduction, and FACS analysis is performed 2 weeks after the introduction to compare the intensity of red fluorescence.
- the results show that the anti-silencing and activity-enhancing effects of the 2.5 kb fragment on UBCP increase the proportion of mcherry-expressing cells.
- Example 15 Construction of mCherry expression vector for random insertion using EF1A promoter to which UbC gene upstream genomic sequence was added
- Expression unit composed of EF1AP/red fluorescent protein mCherry gene coding region/and SV40polyA sequence constructed in Example 7
- a HAC introduction vector pEFms vector; top of FIG. 12
- an expression unit consisting of an EF1AP / mCherry gene / SV40polyA sequence added with about 2.5 kb of the human UbC gene 5' upstream genome sequence HAC introduction with Using the vector (pEF2.5ms vector; second from the top in FIG.
- Example 16 Examination of anti-silencing effect and activity-enhancing effect of additional sequence element on EF1A-mCherry-NeoR expression unit in random insertion gene transfer in CHO cells pEFmNs vector and pEF2.5mNs vector prepared in Example 15 was introduced into 21HAC2/CHOhprt- cells in the same manner as in Example 13. Unlike Example 2 and the like, since a recombination enzyme (Cre) expression vector was not introduced simultaneously, neomycin (G418) resistance is obtained when the introduced vector is randomly inserted into the CHO cell genome.
- Re recombination enzyme
- the vector was digested with restriction enzyme ScaI, it was recovered by ethanol precipitation and introduced into 21HAC2/CHOhprt- by electric pulse method using NEPA21 (Nepagene, 150 V, 5.0 msec). After induction by electric pulse, the cells were seeded on two 10 cm dishes, and after 48 hours, cultured in Ham's F12 medium containing 800 ⁇ g/mL G418 (Wako) and 10% FBS (Nichirei) to form drug-resistant colonies. obtained. Four weeks after the introduction, FACS analysis was performed on the resulting cell population in which drug-resistant colonies were mixed, and red fluorescence intensity was compared. The results are shown in FIG.
- a protein encoded by the DNA of interest can be stably and efficiently produced in said mammalian cell. It is useful for the purpose of producing
- SEQ ID NOS: 3-8 Primers SEQ ID NOS: 9-10: Annealing sequences for producing DNA fragments containing AscI site and SmaI site SEQ ID NOS: 11-14: Primers SEQ ID NOS: 15-16: DNA containing SalI site and KpnI site Annealing sequences for making fragments SEQ ID NO: 17-18: primers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(1)配列番号1で示される塩基配列又はそれと85%以上の配列同一性を有する塩基配列の中の850以上の塩基配列を含む、プロモーター活性化配列。
(2)(1)に記載のプロモーター活性化配列、プロモーター、及び目的DNAを含む発現ベクター。
(3)前記プロモーターが、構成的発現プロモーターである、(2)に記載の発現ベクター。
(4)前記構成的発現プロモーターが、EF1αプロモーター、PGKプロモーター、及びUBCプロモーターからなる群から選択される、(3)に記載の発現ベクター。
(5)(1)に記載のプロモーター活性化配列を、前記プロモーターの5’側上流に含む(2)~(4)のいずれかに記載の発現ベクター。
(6)哺乳動物の人工染色体ベクターである、(2)~(5)のいずれかに記載の発現ベクター。
(7)ヒト人工染色体ベクターである、(6)に記載の発現ベクター。
(8)(2)~(7)のいずれかに記載の発現ベクターを保持する哺乳動物細胞。
(9)前記動物細胞がヒト細胞又はCHO細胞である、(8)に記載の細胞。
(10)前記ヒト細胞が、ヒト多能性幹細胞又はヒト体性幹細胞である、(9)に記載の細胞。
(11)前記ヒト多能性幹細胞がヒトiPS細胞又はヒトES細胞であり、前記ヒト体性幹細胞がヒトMSC細胞である、(10)に記載の細胞。
(12)(1)に記載のプロモーター活性化配列の存在により、前記目的DNAの安定的な高発現を示す、(8)~(11)のいずれかに記載の細胞。
(13)前記目的DNAの安定的な高発現が、前記目的DNAの発現増強活性及び/又は抗サイレンシング活性によりもたらされる、(12)に記載の細胞。
(14)(2)~(7)のいずれかに記載の発現ベクターを保持する非ヒト哺乳動物。
(15)(8)~(13)のいずれかに記載の哺乳動物細胞を、動物細胞培養用の培地内で培養し、該培養により得らえた培養物から前記目的DNAがコードするタンパク質を採取することを含む、前記目的DNAによりコードされるタンパク質を製造する方法。
(16)(2)~(7)のいずれかに記載の発現ベクターを細胞に導入することにより、該細胞において、前記目的DNAのサイレンシングを抑制する方法。
(17)(2)~(7)のいずれかに記載の発現ベクターを細胞に導入することにより、該細胞において、前記目的DNAの発現を増強する方法。
本明細書は本願の優先権の基礎となる日本国特許出願番号2021-186122号の開示内容を包含する。
本発明のプロモーター活性化配列は配列番号1で示される塩基配列又はその塩基配列において変異を有する塩基配列の中の850以上の塩基配列を含む。配列番号1で示される塩基配列は、ヒト染色体DNA上のUbC遺伝子の発現プロモーターの、更に上流に位置する配列である。より具体的には配列番号1で示される塩基配列は、ヒト12番染色体の124,927,045~124,929,593番に対応する2549bpの塩基配列である。ヒト12番染色体の塩基配列は、米国生物工学情報センター(NCBI;National Center for Biotechnology Information)のGenBankにNC_000012.12として開示されている。配列番号1の塩基配列を表1に示す。
本発明の発現ベクターは1.に記載のプロモーター活性化配列、プロモーター、及び目的DNAを含む。
上記の外来遺伝子発現用ベクターを、宿主細胞である哺乳動物細胞に導入することにより、本発明の発現ベクターを含む哺乳動物細胞(以下、単に本発明の哺乳動物細胞と略記する)を作製することができる。
3.に記載の哺乳動物細胞を、動物細胞培養用の培地内で培養し、該培養により得らえた培養物から前記目的DNAがコードするタンパク質(以下、所望のタンパク質と称する)を採取することにより、所望のタンパク質を製造することができる。上記で述べたように、本発明のプロモーター活性化配列の存在により目的DNAの安定的な高発現をもたらすからである。
本発明はさらに、本発明の発現ベクターを保持する非ヒト動物を提供する。本明細書中の「非ヒト動物」という用語は、ヒトを除く、サル、チンパンジーなどの霊長類、マウス、ラット、ハムスター、モルモットなどの齧歯類、ウシ、ブタ、ヒツジ、ヤギ、ウマ、ラクダ科動物等の有蹄類などの哺乳動物を含むが、これらに限定されない。
本発明の発現ベクターを哺乳動物、特にヒトに投与し、該哺乳動物の体内で目的DNAがコードするタンパク質を発現させることにより、遺伝子治療を行うことができる。
HACベクター(21HAC2)を保持するCHO hprt欠損(hprt-)細胞株(21HAC2/CHOhprt-;Kazuki Y et al. Gene Ther 18(4):384-93 2011)において、汎用プロモーターに対する付加配列要素の抗サイレンシング効果及び活性増強効果を検討した。I-EGFP-I-loxP-3’HPRTベクター(図2;Kazuki Y et al. Gene Ther 18(4):384-93 2011)のCAGプロモーター-EGFP-polyA部分が、他の様々な発現ユニットと置換されたベクターを、Cre発現ベクター(Kazuki Y et al. Gene Ther 18(4):384-93 2011)と同時に21HAC2/CHOhprt-にトランスフェクションすることで、1コピーの当該発現ユニットが21HAC2に挿入されたHAT耐性クローンが得られる(図2)。
I-EGFP-I-loxP-3’HPRTベクターを鋳型として、HS4(トリインシュレーター配列要素)とNotI/SalI/SpeIを含む断片を増幅した。下記プライマー及びPrimestar GXL premix(タカラ)を用い、98℃10秒→68℃4分、35サイクルのPCR反応を行った。またI-EGFP-I-loxP-3’HPRTベクターを制限酵素NcoI(NEB)及びSpeI(NEB)で消化し、上記増幅した断片を挿入してX3.1-MCSベクター(図3)を作製した。ヒトユビキチンCコアプロモーター(約1.2kb、Schorpp M et al. Nucleic Acids Res. 24(9):1787-1788 1996)、赤色蛍光タンパク質mCherry(Nathan C et al. Nat Biotechnol 22(12):1567-72 2004)遺伝子コード領域、及びSV40polyA配列からなる発現ユニットについては、その両端にNotI部位が配置されるように設計し、その配列をベクタービルダー社にて合成した。NotI(NEB)で消化したX3.1-MCSベクターに、上記合成DNA由来のUbCP-mCherry-SV40pA配列(NotI断片)を挿入して、X3.1-UbCP-mCherry-SV40pAを作製した(図3;以下、pUmsベクターと称す)。
HS4-R1:5’-ATAACTAGTCGACGCGGCCGCCTCACTGACTCCGTCCTGGA-3’(配列番号4)
ヒトUbC遺伝子5’上流ゲノム配列約15kb (以下UL15と称す)内の約2.5kb領域(図1)又はその部分断片(0.8kb;図1)がそれぞれ付加された、UbCP/mCherry遺伝子/SV40ポリA配列からなる発現ユニットを持つHAC導入用ベクターを以下の手順で作製した(それぞれ、pUL0.8msベクター、pUL2.5msベクターと称す)。2種のヒトUbC遺伝子5’上流ゲノム配列は、下記のプライマーをそれぞれ用い、ヒト染色体BACクローンRP11-592O2を鋳型としたPCR増幅により調製した。下記のプライマー及びPrimestar GXL premix(タカラ)を用い、98℃10秒→72℃10分、5サイクル、98℃10秒→70℃10分、5サイクル、98℃10秒→68℃10分、30サイクルのPCR反応を行った。さらに増幅断片をSalIお及びKpnIで消化し、得られた断片をSalI及びKpnIで消化されたpUmsベクターにクローニングした。ベクターの構築について概略を図4に示す。
pUL0.8ms-R:5’-AGTGGTACCCGCACGCAGTCCCTGCTGAA-3’(配列番号6)
pUL2.5ms-F:5’-CATGTCGACACCCGGAAGGCGGAGGTTAC-3’(配列番号7)
pUL2.5ms-R:5’-AGTGGTACCAGGAAGTTCAGGAAATTGGC-3’(配列番号8)
UL15が付加されたUbCP/mCherry遺伝子/SV40ポリA配列からなる発現ユニットを持つHAC導入用ベクターを以下の手順で作製した。pSTV28ベクター(タカラ)をEcoRI及びXbaIで消化し、下記合成DNA配列をアニーリングして作製したAscIサイト及びSmaIサイトを含むDNA断片を挿入し、pSTV28+MCSベクターを作製した(図5)。
pSTV28-MCS_2: 5’-AATTCGGCGCGCCAATCCCGGGT-3’(配列番号10)
pUL4ms-R:5’-GAGGTCGACCGGGAGCGGGTGGGCGGCCC-3’(配列番号12)
pUL11ms-F:5’-TATGTCGACATCGATATACAGACATGAGCTAATGT-3’(配列番号13)
pUL11ms-F:5’-AGTGGTACCAGGAAGTTCAGGAAATTGGC-3’(配列番号14)
実施例1で作製したpUmsベクター又はpUL2.5msベクターを、21HAC2/CHOhprt-細胞中の21HAC2ベクターへ挿入した。上記発現ベクターを組み換え酵素(Cre)発現ベクターpBS185(Kazuki Y et al. Gene Ther 18(4):384-93 2011)とともに21HAC2ベクターを保持する21HAC2/CHOhprt-細胞へNEPA21(ネッパジーン、150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ1枚に細胞を播種し、48時間後に2%HAT(Sigma)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、HAT耐性コロニーを取得した。得られたHAT耐性細胞集団について導入から7週間後にFACS解析を行ない、赤色蛍光タンパク質の発現を評価した。その結果を図7に示す。pUL2.5msベクターが導入されたHAT耐性細胞集団の陽性ピーク中央値の平均(4302)は、pUmsベクターが導入された細胞集団の陽性ピーク中央値の平均(1662)より高かった。すなわちUBCPへ2.5kb断片を付加することにより、プロモーター活性増強効果がもたらされることが示された。
実施例1で作製したpUmsベクター、pUL0.8msベクター、pUL2.5msベクターを、21HAC2/ヒト不死化間葉系幹細胞(Okamoto T et al. BBRC 295:354-361 2002)hprt-株中の21HAC2ベクターへ挿入した。上記発現ベクターを組み換え酵素(Cre)発現ベクターpBS185(Kazuki Y et al. Gene Ther 18(4):384-93 2011)と共に、21HAC2ベクターを保持する21HAC2/hiMSChprt-細胞へNEPA21(ネッパジーン,150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュに細胞を播種し、48時間後に2%HAT(Sigma)と10% FBS(ニチレイ)を含むDMEM培地で培養し、HAT耐性コロニーを取得した。得られたHAT耐性細胞について、導入から2週間後に顕微鏡下で赤色蛍光タンパク質の発現を観察した結果を、明視野像と共に図8に示す。pUmsベクター、及びpUL0.8msベクターが導入された細胞における赤色蛍光強度と比較して、pUL2.5msベクターが導入された細胞における赤色蛍光強度は明らかに強かった。すなわちUBCPへの約2.5kb断片の付加は、プロモーター活性増強効果をもたらすこと、及び約0.8kb断片の付加はその効果が無いことが示された。
φC31 attB-NeoR-pUbc-KO1ベクター(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021に記載)は、ヒトユビキチンCコアプロモーター(約1.2kb、Schorpp M et al. Nucleic Acids Res. 24(9): 1787-1788 1996)、オレンジ色蛍光タンパク質KO(MBL)遺伝子コード領域、及びウシ成長ホルモン遺伝子由来polyA配列からなる発現ユニットを含む。該ベクターをφC31インテグラーゼ発現ベクター(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021)と同時にBasal-HAC/CHO細胞にトランスフェクションすることで、1コピーの当該発現ユニットがBasal-HACに挿入されたG418耐性クローンが得られる(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021)。
XhoI-KpnI-SalI: 5’- TCGACGCATGGTACCGACTC -3’(配列番号16)
また実施例1で作製したpSTV28+MCSベクターのPvuIサイトからSacIサイト間のDNA断片を、pULベクターのUbC-KO-BGHpAを含むPvuIからSacIサイト間のDNA断片と置換して、pSTV-UbC-hKO-BGHpAベクターを作製した(以下、pSUkbベクターと称す;図10)。pSUkbベクターをSalI及びKpnIで消化し、pSUL15msベクターのSalIサイトからKpnIサイト間のUbC遺伝子5’上流のゲノム配列約15kbを含むDNA断片を挿入してpSUL15ベクターを作製した(図10)。
実施例4で作製したpULベクター、pUL2.5ベクター、pSUL15ベクターを、Basal-HAC/CHO細胞中のBasal-HACベクターへ挿入した。上記発現ベクターを組み換え酵素(φC31インテグラーゼ)発現ベクター(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021)と共に、Basal-HAC/CHO細胞へNEPA21(ネッパジーン,150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、96 wellプレートに細胞を播種し、48時間後にG418(Wako)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、G418耐性コロニーを単離し拡大培養した。各ベクターについて5個以上のクローンを選択してFACS解析を行ない、オレンジ色蛍光タンパク質の発現を評価した。その結果を図11に示す。pULベクターの6クローンの陽性ピーク中央値の平均は1300であり、pUL2.5ベクター及びpUL15ベクターにおいてはそれぞれ平均14400、14000であった。またpULベクターの6クローンのうち、2クローンは陰性集団の割合が陽性集団より高かったが、pUL2.5ベクター及びpSUL15ベクターにおいては、6クローン全てにおいて陰性集団は観察されなかった。すなわち2.5kb断片の付加は、15kb断片の付加と同等レベルの発現増強活性と抗サイレンシング活性をもたらすことが示された。
実施例4で作製したpULベクター、pUL2.5ベクターを、Basal-HAC/ヒトiPS細胞(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021)中のBasal-HACベクターへ挿入した。上記発現ベクターを組み換え酵素(φC31インテグラーゼ)発現ベクター(Kazuki Y et al. Molecular Therapy: Nucleic Acids 23:629-639 2021)と共に、Basal-HAC/ヒトiPS細胞へ電気パルス法により導入した。電気パルスにて導入した後、96 wellプレートに細胞を播種し、48時間後にG418(90μg/mL)を含むStemFit培地(TAKARA)で培養し、G418耐性コロニーを単離し拡大培養した。各ベクターについて12個以上のシングルクローンを選択しFACS解析を行ない、オレンジ色蛍光タンパク質Kusabira Orange(KO)の発現を評価した。各ベクターを導入したクローンにおけるKOの蛍光強度を評価した結果を図20に示す。その結果、pUL2.5ベクターを導入した場合のKO陽性集団の割合は、pULベクターを導入した場合と比較して高かったことから、2.5kb断片のUBCPに対する抗サイレンシング効果及び活性増強効果により、ヒトiPS細胞においてKO発現細胞の割合が高まることが示された。
ヒトelongation factor1α1(EF1α)遺伝子プロモーター(EF1AP;約1.2kb、Qin JY et al. PLoS One. 5(5): e10611 2010)、赤色蛍光タンパク質mCherry遺伝子コード領域、及びSV40polyA配列からなる発現ユニットについては、その両端にNotI部位が配置されるように設計し、その配列をベクタービルダー社にて合成した。実施例1と同様にNotIで消化したX3.1-MCSベクターに、上記合成DNA由来のEF1A-mCherry-SV40pA配列(NotI断片)を挿入して、X3.1-EF1A-mCherry-SV40pAを作製した(以下、pEFmsベクターと称す;図12)。実施例1と同様に、ヒトUbC遺伝子5’上流ゲノム配列約2.5kbがそれぞれ付加されたEF1AP/mCherry遺伝子/SV40ポリA配列からなる発現ユニットを持つHAC導入用ベクターを作製した(以下、pEF2.5msベクターと称す;図12)。
実施例7で作製したpEFmsベクター、pEF2.5msベクターを21HAC2/CHOhprt-細胞中の21HAC2ベクターへ挿入した。上記発現ベクターを組み換え酵素(Cre)発現ベクターpBS185(Kazuki Y et al. Gene Ther 18(4):384-93 2011)と共に、21HAC2ベクターを保持する21HAC2/CHOhprt-細胞へNEPA21(ネッパジーン,150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ1枚に細胞を播種し、48時間後に2%HAT(Sigma)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、HAT耐性コロニーを取得した。得られたHAT耐性細胞集団について導入から4週間後と7週間後にFACS解析を行ない、赤色蛍光タンパク質の発現を評価した。その結果を図13に示す。pEFmsベクターが導入されたHAT耐性細胞集団においては、mcherry陰性集団の割合が陽性集団より高かったが、pUL2.5ベクターが導入された細胞集団においては、陰性集団はほとんど観察されなかった。すなわちEF1APへの2.5kb断片を付加することにより、抗サイレンシング効果がもたらされることが示された。
ヒトphosphoglycerate kinase 1(PGK)遺伝子プロモーター(PGKP;約0.5kb、Kita-Matsuo H et al. PLoS One. 4(4): e5046. 2009)、赤色蛍光タンパク質mCherry遺伝子コード領域、及びSV40polyA配列からなる発現ユニットについては、その両端にNotI部位が配置されるように設計し、その配列をベクタービルダー社にて合成した。実施例1と同様にNotIで消化したX3.1-MCSベクターに、上記合成DNA由来のPGKP-mCherry-SV40pA配列(NotI断片)を挿入してX3.1- PGKP-mCherry-SV40pAを作製した(以下、pPGKmsベクターと称す;図12)。実施例1と同様に、ヒトUbC遺伝子5’上流ゲノム配列約2.5kbが付加されたPGKP/mCherry遺伝子/SV40ポリA配列からなる発現ユニットを持つHAC導入用ベクターを作製した(以下、pPGK2.5msベクターと称す;図12)。
実施例9で作製したpPGKmsベクター、pPGK2.5msベクター、pPGK4msベクターを、21HAC2/CHOhprt-細胞中の21HAC2ベクターへ挿入した。上記発現ベクターを組み換え酵素(Cre)発現ベクターpBS185(Kazuki Y et al. Gene Ther 18(4):384-93 2011)と共に、21HAC2ベクターを保持する21HAC2/CHOhprt-細胞へNEPA21(ネッパジーン,150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ1枚に細胞を播種し、48時間後に2%HAT(Sigma)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、HAT耐性コロニーを取得した。得られたHAT耐性細胞集団について導入から4週間後と7週間後にFACS解析を行ない、赤色蛍光タンパク質の発現を評価した。その結果を図14に示す。pPGKmsベクターが導入されたHAT耐性細胞集団においては、mcherry陰性集団の割合が陽性集団より高かった。一方pPGK2.5msベクターが導入された細胞集団においては、陰性集団はほとんど観察されなかった。すなわちEF1APへの2.5kb断片の付加により、抗サイレンシング効果がもたらされることが示された。
実施例9で作製したpPGKmsベクター、pPGK2.5msベクターを、21HAC2/CHOhprt-細胞中の21HAC2ベクターへ挿入した。上記発現ベクターを組み換え酵素(Cre)発現ベクターpBS185(Kazuki Y et al. Gene Ther 18(4):384-93 2011)と共に、21HAC2ベクターを保持する21HAC2/hiMSChprt-細胞へNEPA21(ネッパジーン,150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュに細胞を播種し、48時間後に2%HAT(Sigma)と10% FBS(ニチレイ)を含むDMEM培地で培養し、HAT耐性コロニーを取得した。得られたHAT耐性細胞集団について導入から4週間後にFACS解析を行ない、赤色蛍光タンパク質の発現を評価した。その結果を図15に示す。pPGKmsベクターが導入されたHAT耐性細胞集団においては、mcherry陰性集団の割合が陽性集団より高かった。一方pPGK2.5msベクターが導入された細胞集団においては、陰性集団はほとんど観察されなかった。すなわちPGKPへの2.5kb断片の付加により、抗サイレンシング効果がもたらされることが示された。
ヒトUbC遺伝子5’上流ゲノム配列約15kb内の約2.5kb領域(図1)が付加された、UbCP/mCherry―NeoR(ネオマイシン耐性)融合遺伝子/SV40ポリA配列からなる発現ユニットを持つランダム挿入用ベクターを以下の手順で作製した(pUL2.5mNsベクターと称す)。
FseI_NeoR Rv:5’- CTTAGGCCGGCCACTCGAGTCAGAAGAACTCGTCAAGAAGGCG -3’(配列番号18)
実施例12で作製したpUmNsベクター、pUL2.5mNsベクターを21HAC2/CHOhprt-細胞へ導入した。実施例2等と異なり、組み換え酵素(Cre)発現ベクターを同時に導入しなかった。それにより、導入されたベクターがCHO細胞ゲノムにランダムに挿入された場合にネオマイシン(G418)耐性となる。上記ベクターを制限酵素ScaIで消化後、エタノール沈殿法で回収して21HAC2/CHOhprt-へNEPA21(ネッパジーン、150V, 5.0msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ2枚に細胞を播種し、48時間後に800μg/mLのG418(Wako)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、薬剤耐性コロニーを取得した。導入から2週間後に、得られた薬剤耐性コロニーを混合した細胞集団についてFACS解析を行い、赤色蛍光強度を比較した。その結果を図18に示す。pUmNsベクターを有するG418耐性細胞においては、全細胞数に対するmCherry陽性(P7の画分)の細胞数は、20826個中1136個(5.5%)であった。pUL2.5mNsベクターを有するG418耐性細胞においては、全細胞数に対するmCherry陽性(P7の画分)の細胞数は、12595個中1481個(11.8%)であった。さらに導入から2週目、4週目、7週目において、薬剤耐性細胞集団のFACS解析によって全細胞数に対するmCherry強陽性画分の割合を評価した結果を図21-1と図21-2に示す。図21-1の太い四角で囲まれた部分はmCherry強陽性画分(P6)を示す。図21-2は電気パルスによる導入から2週間目、4週間目、又は7週間目のG418耐性細胞についてFACS解析を行ない、全細胞数に対するmCherry強陽性画分(P6)の割合を測定した示す。3つの独立した遺伝子導入実験において、蛍光強度1000以上を示すmCherry強陽性画分(P6)の細胞の割合は、pUL2.5mNsベクターを有する4週目と7週目のG418耐性細胞においては全て10%以上(4週目の平均:15.87%、7週目の平均:13.10%)であったのに対して、pUmNsベクターを有するG418耐性細胞においては、全て0.1%以下であった。以上、pUL2.5mNsベクターを導入した場合のmcherry陽性集団の割合は、pUmNsベクターを導入した場合と比較して高かったことから、2.5kb断片のUBCPに対する抗サイレンシング効果及び活性増強効果により、mcherry発現細胞の割合が高まることが示された。
実施例12で作製したpUmNsベクター、pUL2.5mNsベクターをヒトiPS細胞(201B7:RIKEN CELL BANK No.HPS0063)へ導入した。実施例2等と異なり、組み換え酵素(Cre)発現ベクターを同時に導入しない。それにより、導入されたベクターがCHO細胞ゲノムにランダムに挿入された場合にネオマイシン(G418)耐性となる。上記ベクターを制限酵素ScaIで消化後、エタノール沈殿法で回収して201B7へNEPA21(ネッパジーン、175V, 2.5msec)を用いて電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ2枚に細胞を播種し、48時間後に70μg/mLのG418(Wako)を含むStemFit培地(TAKARA)で培養し、薬剤耐性コロニーを取得した。導入から7日後に10cmディッシュ1枚についてメタノールで15分処理した後、CBB染色液(0.25%CBB/10%エタノール/40%メタノール)で15分染色した。染色処理した10cmディッシュを撮影し、コロニー数を計測・比較した。その結果、2.5kb断片のUBCPに対する抗サイレンシング効果及び活性増強効果により、薬剤耐性コロニー出現率が高まった(図19)。さらに10cmディッシュ1枚について導入後8日以降はG418濃度を50μg/mlに変えて培養し、導入2週間後にFACS解析を行い、赤色蛍光強度を比較する。その結果、2.5kb断片のUBCPに対する抗サイレンシング効果及び活性増強効果により、mcherry発現細胞の割合が高まることが示される。
実施例7で構築した、EF1AP/赤色蛍光タンパク質mCherry遺伝子コード領域/及びSV40polyA配列からなる発現ユニットを含むHAC導入用ベクター(pEFmsベクター;図12の1番上)、およびヒトUbC遺伝子5’上流ゲノム配列約2.5kbが付加されたEF1AP/mCherry遺伝子/SV40polyA配列からなる発現ユニットを持つHAC導入用ベクター(pEF2.5msベクター;図12の上から2番目)をそれぞれ出発材料として、mCherry遺伝子を[実施例12]で示したmCherry-NeoR(ネオマイシン耐性)融合遺伝子と置換することにより、pEFmNsベクター(図22)、およびpEF2.5mNsベクター(図22)を構築した。
実施例15で作製したpEFmNsベクター、pEF2.5mNsベクターを実施例13と同様に21HAC2/CHOhprt-細胞へ導入した。実施例2等と異なり、組み換え酵素(Cre)発現ベクターを同時に導入することは行なわなかったため、導入されたベクターがCHO細胞ゲノムにランダムに挿入された場合にネオマイシン(G418)耐性となる。上記ベクターを制限酵素ScaIで消化後、エタノール沈殿法で回収し、NEPA21(ネッパジーン、150V, 5.0msec)を用いて、21HAC2/CHOhprt-へ電気パルス法により導入した。電気パルスにて導入した後、10cmディッシュ2枚に細胞を播種し、48時間後に800μg/mLのG418(Wako)と10% FBS(ニチレイ)を含むHam’s F12培地で培養し、薬剤耐性コロニーを取得した。導入から4週間後に、得られた薬剤耐性コロニーを混合した細胞集団についてFACS解析を行い、赤色蛍光強度を比較した。その結果を図23に示す。なおpEFmNsベクターについては3回の、pEF2.5mNsベクターについては2回の独立した実験の結果が示されている。pEFmNsベクターを有するG418耐性細胞においては、全細胞数におけるmCherry蛍光強度の中央値は、それぞれ649、828、509、またmCherry陽性細胞の割合は、それぞれ67%、77.42%、62.56%であった。一方pEF2.5mNsベクターを有するG418耐性細胞においては、全細胞数におけるmCherry蛍光強度の中央値は、それぞれ2986、2625、またmCherry陽性細胞の割合は、それぞれ94.15%、89.22%、であった。以上、pEF2.5mNsベクターを導入した場合のmcherry陽性集団の割合は、pEFmNsベクターを導入した場合と比較して高かったことから、2.5kb断片のEF1Aプロモーターに対する抗サイレンシング効果及び活性増強効果により、mcherry発現細胞の割合が高まることが示された。
配列番号9~10:AscIサイト及びSmaIサイトを含むDNA断片を作製するためのアニーリング配列
配列番号11~14:プライマー
配列番号15~16:SalIサイト及びKpnIサイトを含むDNA断片を作製するためのアニーリング配列
配列番号17~18:プライマー
Claims (13)
- 配列番号1で示される塩基配列又はそれと85%以上の配列同一性を有する塩基配列の中の850以上の塩基配列を含む、プロモーター活性化配列。
- 請求項1に記載のプロモーター活性化配列、プロモーター、及び目的DNAを含む発現ベクター。
- 前記プロモーターが、構成的発現プロモーターである、請求項2に記載の発現ベクター。
- 前記構成的発現プロモーターが、EF1αプロモーター、PGKプロモーター、及びUBCプロモーターからなる群から選択される、請求項3に記載の発現ベクター。
- 請求項1に記載のプロモーター活性化配列を、前記プロモーターの5’側上流に含む請求項2~請求項4のいずれか1項に記載の発現ベクター。
- 哺乳動物の人工染色体ベクターである、請求項2~請求項5のいずれか1項に記載の発現ベクター。
- ヒト人工染色体ベクターである、請求項6に記載の発現ベクター。
- 請求項2~請求項7のいずれか1項に記載の発現ベクターを保持する哺乳動物細胞。
- 前記動物細胞がヒト細胞又はCHO細胞である、請求項8に記載の細胞。
- 前記ヒト細胞が、ヒト多能性幹細胞又はヒト体性幹細胞である、請求項9に記載の細胞。
- 前記ヒト多能性幹細胞がヒトiPS細胞又はヒトES細胞であり、前記ヒト体性幹細胞がヒトMSC細胞である、請求項10に記載の細胞。
- 請求項2~請求項7のいずれか1項に記載の発現ベクターを含む非ヒト哺乳動物。
- 請求項8~請求項11のいずれか1項に記載の哺乳動物細胞を、動物細胞培養用の培地内で培養し、該培養により得らえた培養物から前記目的DNAがコードするタンパク質を採取することを含む、前記目的DNAによりコードされるタンパク質を製造する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-186122 | 2021-11-16 | ||
JP2021186122 | 2021-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023090372A1 true WO2023090372A1 (ja) | 2023-05-25 |
Family
ID=86397102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/042594 WO2023090372A1 (ja) | 2021-11-16 | 2022-11-16 | プロモーター活性化配列、そのプロモーター活性化配列を含む発現ベクター、及びその発現ベクターを含む哺乳動物細胞 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023090372A1 (ja) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
WO2006048291A2 (en) * | 2004-11-03 | 2006-05-11 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008013067A1 (fr) | 2006-07-07 | 2008-01-31 | Kyowa Hakko Kirin Co., Ltd. | Vecteur de chromosome artificiel humain (cah), et substance pharmaceutique à base de cellules humaines contenant un vecteur de chromosome artificiel humain (cah) |
JP2010004887A (ja) | 2002-10-04 | 2010-01-14 | Kyowa Hakko Kirin Co Ltd | ヒト人工染色体(hac)ベクター |
WO2011071147A1 (ja) | 2009-12-11 | 2011-06-16 | 協和発酵キリン株式会社 | 新規な発現ベクター及び該ベクターを用いたタンパク質の製造方法 |
JP4895100B2 (ja) | 2006-05-01 | 2012-03-14 | 国立大学法人鳥取大学 | 内在遺伝子を含まないヒト人工染色体ベクター |
JP4997544B2 (ja) | 2007-11-14 | 2012-08-08 | 国立大学法人鳥取大学 | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
JP5557217B2 (ja) | 2010-01-06 | 2014-07-23 | 国立大学法人鳥取大学 | マウス人工染色体ベクター |
WO2018204764A1 (en) * | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
WO2020075823A1 (ja) | 2018-10-10 | 2020-04-16 | 国立大学法人鳥取大学 | 微小核細胞融合法による目的dnaを含む動物細胞の作製方法 |
WO2020223160A1 (en) | 2019-04-30 | 2020-11-05 | Chan Zuckerberg Biohub, Inc. | A novel chromatin-opening element for stable long term gene expression |
JP2021186122A (ja) | 2020-05-27 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
-
2022
- 2022-11-16 WO PCT/JP2022/042594 patent/WO2023090372A1/ja active Application Filing
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
JP2010004887A (ja) | 2002-10-04 | 2010-01-14 | Kyowa Hakko Kirin Co Ltd | ヒト人工染色体(hac)ベクター |
WO2006048291A2 (en) * | 2004-11-03 | 2006-05-11 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP4895100B2 (ja) | 2006-05-01 | 2012-03-14 | 国立大学法人鳥取大学 | 内在遺伝子を含まないヒト人工染色体ベクター |
WO2008013067A1 (fr) | 2006-07-07 | 2008-01-31 | Kyowa Hakko Kirin Co., Ltd. | Vecteur de chromosome artificiel humain (cah), et substance pharmaceutique à base de cellules humaines contenant un vecteur de chromosome artificiel humain (cah) |
JP4997544B2 (ja) | 2007-11-14 | 2012-08-08 | 国立大学法人鳥取大学 | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
WO2011071147A1 (ja) | 2009-12-11 | 2011-06-16 | 協和発酵キリン株式会社 | 新規な発現ベクター及び該ベクターを用いたタンパク質の製造方法 |
JP5557217B2 (ja) | 2010-01-06 | 2014-07-23 | 国立大学法人鳥取大学 | マウス人工染色体ベクター |
WO2018204764A1 (en) * | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
WO2020075823A1 (ja) | 2018-10-10 | 2020-04-16 | 国立大学法人鳥取大学 | 微小核細胞融合法による目的dnaを含む動物細胞の作製方法 |
WO2020223160A1 (en) | 2019-04-30 | 2020-11-05 | Chan Zuckerberg Biohub, Inc. | A novel chromatin-opening element for stable long term gene expression |
JP2021186122A (ja) | 2020-05-27 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
Non-Patent Citations (32)
Title |
---|
"GenBank", Database accession no. NC 000012.12 |
FASTA, METHODS ENZYMOL., vol. 183, 1990, pages 63 |
GENES DEVELOP, vol. 4, 1990, pages 1288 |
J. A. THOMSON ET AL., BIOL. REPROD., vol. 55, 1996, pages 254 - 259 |
J. A. THOMSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7844 - 7848 |
J. A. THOMSON ET AL., SCIENCE, vol. 282, 1999, pages 1145 - 1147 |
J. A. THOMSONV. S. MARSHALL, CURR. TOP. DEV. BIOL., vol. 38, 1998, pages 133 - 165 |
J. LIAO ET AL., CELL RES., vol. 18, 2008, pages 600 - 603 |
J. YU ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
J. YU ET AL., SCIENCE, vol. 318, pages 1917 - 1920 |
JINEK ET AL., SCIENCE, vol. 17, no. 6096, 2012, pages 816 - 821 |
K. KAWAHARADA ET AL., WORLD J. STEM CELLS, vol. 7, no. 7, 2015, pages 1054 - 1063 |
K. TAKAHASHIS. YAMANAKA, CELL, vol. 126, 2006, pages 663 - 676 |
KAKEDA ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 415, 2011, pages 439 - 444 |
KAKEDA MINORU; NAGATA KEIKO; OSAWA KANAKO; MATSUNO HIROKI; HIRATSUKA MASAHARU; SANO AKIKO; OKAZAKI AKIYO; SHITARA SHINGO; NISHIKAW: "A new chromosome 14-based human artificial chromosome (HAC) vector system for efficient transgene expression in human primary cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 415, no. 3, 22 October 2011 (2011-10-22), Amsterdam NL , pages 439 - 444, XP028596999, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2011.10.088 * |
KARLINALTSCHUL, PRO. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
KAZUKI Y ET AL., GENE THER, vol. 18, no. 4, 2011, pages 384 - 93 |
KAZUKI Y ET AL., MOLECULAR THERAPY: NUCLEIC ACIDS, vol. 23, 2021, pages 629 - 639 |
KITA-MATSUO H ET AL., PLOS ONE., vol. 4, no. 4, 2009, pages e5046 |
KUNKEL ET AL., SCIENTIFIC REPORTS, 2017, pages 7 - 7919 |
LOWE ET AL., PROC. NATL. ACAD. SCI., USA, vol. 86, 1989, pages 8227 |
M. J. EVANSM. H. KAUFMAN, NATURE, vol. 292, no. 5819, 1981, pages 154 - 156 |
M. NAKAGAWA ET AL., NAT. BIOTECHNOL., vol. 26, 2008, pages 101 - 106 |
NATHAN C ET AL., NAT BIOTECHNOL, vol. 22, no. 12, 2004, pages 1567 - 72 |
OKAMOTO T ET AL., BBRC, vol. 295, 2002, pages 354 - 361 |
PAULSON ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 17619 |
QIN JY ET AL., PLOS ONE, vol. 5, no. 5, 2010, pages e10611 |
RIVAL-GERVIER ET AL., MOLECULAR THERAPY, vol. 21, 2013, pages 1536 - 1550 |
RUDINA ET AL., BIORXIV, 2019 |
SANDER ET AL., NATURE BIOTECHNOLOGY, vol. 32, no. 4, 2014, pages 347 - 355 |
SCHORPP M ET AL., NUCLEIC ACIDS RES., vol. 24, no. 9, 1996, pages 1787 - 1788 |
TAKAHASHI, K. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101485840B1 (ko) | 마우스 인공염색체 벡터 | |
CN111885915A (zh) | 使用crispr/cas系统对动物进行转录调制 | |
Moghaddassi et al. | TALEN-mediated modification of the bovine genome for large-scale production of human serum albumin | |
CN110184301B (zh) | 通过Tild-CRISPR实现高效精确的靶向整合 | |
US20210015082A1 (en) | Artificial recombinant chromosome and use thereof | |
WO2023234320A1 (ja) | 遺伝子改変ブタの製造方法、樹立された体細胞、及び、遺伝子改変ブタ製造用原料 | |
WO2023090372A1 (ja) | プロモーター活性化配列、そのプロモーター活性化配列を含む発現ベクター、及びその発現ベクターを含む哺乳動物細胞 | |
WO2018126095A1 (en) | Transgenic animals and method for bioproduction | |
KR20220163905A (ko) | 인위적 뉴클레아제를 생산하는 형질전환 동물 및 형질전환 배아 | |
US20220112514A1 (en) | Artificial recombinant chromosome and use thereof | |
KR20240099271A (ko) | 프로모터 활성화 서열, 그 프로모터 활성화 서열을 포함하는 발현 벡터, 및 그 발현 벡터를 포함하는 포유 동물 세포 | |
CN118265798A (en) | Promoter activating sequence, expression vector comprising the same, and mammalian cell comprising the same | |
EP2844064B1 (en) | Transgenic animal model of amyotrophic lateral sclerosis | |
WO2023085433A1 (ja) | ヒト細胞内でヒト人工染色体ベクターを作製する方法 | |
JP7202573B2 (ja) | 哺乳類人工染色体ベクターを利用するタンパク質の高生産方法 | |
WO2023234319A1 (ja) | 遺伝子導入ブタの製造方法、体細胞クローニング原料、遺伝子導入ブタ、樹立された体細胞、及び組織ないし臓器 | |
WO2023176982A1 (ja) | Mhc遺伝子群ヒト化動物 | |
WO2021171688A1 (ja) | 遺伝子ノックイン方法、遺伝子ノックイン細胞作製方法、遺伝子ノックイン細胞、がん化リスク評価方法、がん細胞製造方法、及びこれらに用いるためのキット | |
Shu et al. | Construction of expression vector of human lactoferrin and its expression in bovine mammary epithelial cells | |
Kumari et al. | Transgenic animals in biotechnology | |
KR101628701B1 (ko) | 소 넉-인용 벡터 및 그의 용도 | |
KR20100128156A (ko) | 알파 1,3-갈락토실트랜스퍼라아제 유전자의 위치에 daf 유전자를 넉인한 체세포 제조 방법 | |
Li et al. | Efficient CRSIPR/CAS9-Mediated Oval Gene Replacement with Human ALB in Chicken DF-1 Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22895653 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2023562388 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022895653 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022895653 Country of ref document: EP Effective date: 20240617 |